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Invasive carcinoma of the cervix was compared in women under 
and over 35 years of age in a 10-year cohort study for the 
period 1974 - 1983. The aim was to determine if there were 
any significant differences in disease characteristics and 
survival. A ,non-concurrent prospective study design was 
employed with a follow-up period of at l~ast 5 years. All 
eligible young patients (n = 82) were studied out of a total 
patient population of 1522 and compared with a 13% random 
sample (n = 82) of equally eligible older patients. There 
were three study losses in each group (3,7%), giving a final 
comparison number of 79 . 
. Patient data included disease stage, treatment type and 
complications, recurrence time and site and survival time. 
Tumour pathological characteristics were reviewed and 
evidence of Human Papillomavirus (HPV) was sought on 
histology and cytology specimens. Life table analyses were 
performed on the survival data and compared by the logrank 
test. The covariates of disease stage, treatment type and 
tumour type were included in the analysis of the effect of 
age group on survival. Multivariate analysis with a 
proportional hazards general linear model was performed for 
simultaneous control of confounding factors. Other disease 
characteristics were compared using the Chi-square test. 
The overall proportion of young women was 11,6%. (This 
did not change for the period 1984 1988.) Five-year 
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survival was 57% for the young and 46% for the older group 
(not statistically significant: p = 0,198). There was no 
statistically significant difference in a number of 
characteristics, including tumour size, endocervical site, 
grade or type. There were 8 non-squamous tumours in the 
young {10%). Residual disease, time to recurrence, rate and 
site of distant metastasis, and treatment of recurrent 
tumour did not differ significantly; nor did rate of spread 
to lymph nodes, adequacy of follow-up or treatment 
complications. Evidence of HPV was found in 35% of 
evaluable histology and 21% of malignant cytology. There 
was no significant excess of HPV in the young group. The 
same applied to the length of the preinvasive phase and the 
false negative cytology rate - no significant differences 
were found. 
There were significantly more Stage lB tumours in the young 
group (p = 0,01), surgery was used more often for treatment 
in young patients (p = 0,027) and the difference in survival 
between the disease stages was highly significant (p 
0,0001). Multivariate analysis showed _that the effect of 
age on survival was non-significant (p = 0,850). 
The conclusion of the study is that cervical carcinoma 
in young women is not a different disease with a worse 
prognosis than in older women. Furthermore, it is not 
becoming more common in t _he young locally. Young women tend 
more often to have early stage disease. 
1 
1. INTRODUCTION 
1.1 CARCINOMA OF THE CERVIX 
Invasive carcinoma of the uterine cervix is, overall, 
the most common cancer in females in the world1 . In 
the developed world it may comprise as little as 5% of 
all female cancers and be far exceede~ in incidence by 
other cancers, e.g. carcinoma of the breast or of the 
uterine corpus, but in parts of the developing world it 
may comprise up to 35% of all cancer in females1 . The 
percentage lifetime risk from birth to age 74 for inva-
sive carcinoma of the cervix approaches 7% in Columbia; 
in the United Kingdom it is 1.25%.2 For the entire 
United States of America t.he average annual age ad-
justed incidence of squamous cell carcinoma of the 
cervix for 1976 was 13,7 per 100 000 white women. 2 For 
Black women in South Africa it was 60 per 100 000 in 
1986. 8 The incidence rate is as high as 85 per 100 000 
women in certain areas of Panama. 
A number of risk factors for developing invasive 
cervical carcinoma have been identified, which may 
partly explain the differing incidences noted above. 
In 1842 Rigoni~stern commented on the vastly different 
incidence of cervical cancer in prostitutes when com-
pared to nuns, and this led to a large number of epi-
demiological studies which have confirmed the impor-
tance of a sexually transmitted agent in the aetiology 
of cervical cancer. 3 Age of first intercourse below 17 
years is the most powerful sexual discriminating vari-
able. There are however a number of very important 
covariables associated with the putative sexually 
transmitted agent; these are socio-economic class, to-
bacco smoking and the use of oral contracep-
tives .1, 3, 4, 5 The interrelationship is complex as the 
latter three factors are also related to sexual be-
haviour. The implicated sexually transmitted agent has 
variously been thought to be: gonorrhoea, syphilis, 
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trichomoniasis, basic sperm proteins, herpes simplex 
virus (HSV) type 2, Chlamydia trachomatis, cyto-
megalovirus and human papillomavirus (HPV)3,4,6,10,12. 
Recent DNA hybridization studies have tended to dis-
count the importance of HSV3, 10, 12 and the sexually 
transmitted agent currently felt to be most directly 
related to the development of cervical carcinoma is 
HPV, in association with an undetermined cofactor or 
cofactors. 9- 13 
Survival in the individual patient with invasive 
carcinoma of the cervix is not uniform and is dependent 
on a number of factors, which can be termed prognostic 
factors. Overall survival rates are meaningless in the 
individual or in discrete groups unless corrected for 
these prognostic variables. The overall, global, 5-
year survival rate for invasive carcinoma of the cervix 
is between 50 and 55%.1, 7 This may vary between 0% and 
100% depending on certain prognostic factors. Through-
out the Western world there has been noted to be a 
marked rise in the mortality rate (of the order of 2 to 
4 times greater) in young women, i.e. women aged 15 to 
34 years, during the years 1960 to 1980.1 
Recognised independent prognostic factors are: 
tumour stage, tumour type, tumour grade, tumour size, 
channel invasion status, depth of tumour invasion into 
the cervix and lymph node metastases.4,7,8,22-29,48,80 
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Even in this conservative listing there is still much 
controversy. For example, there are studies which show 
no difference in outcome by tumour type or tumour 
grade.30-32 There are also many more prognostic vari-
ables under investigation. These include evidence of 
extension into the uterine corpus and patient age.23,33 
There are certain variables of importance in radio-
therapy, e.g. prior subtotal hysterectomy or uterine 
position; also pretreatment haematocrit or pretreat-
ment neutrophil count.34 Coexistent pregnancy and 
endocervical geographical site are said not to be of 
independent prognostic significance, but there is room 
for doubt in both cases.3 6 , 37 Race, Parity and meno-
pausal state have been investigated in the past and are 
not accepted prognostic variables.58, 37,38,48 The 
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same applies to duration of symptoms. 40 Recent 
negative cytology (i.e. within 1 year of diagnosis) 
might indi-cate a rapidly progressive or fast growing 
tumour. 41- 46 
It is clearly difficult to separate out one factor 
from all the other potential influences. It would seem 
that tumour ,size, site and invasiveness, together with 
host resistance must be the important conceptual 
aspects of the problem of prognosticating in the 
individual case. 
Treatment with either surgery or radiotherapy 
gives equal survival, although there is room for doubt 
in the individual case, particularly for non-squamous 
and/or bulky endocervical tumours.22,25,49 Neither . 
surgery nor radiotherapy nor their combination is 
adequate for disease which has spread (including micro-
scopically) beyond the pelvis and there is increasing 
interest in adjuvant ( or adjunctive) chemotherapy in 
cervical carcinoma.2 2 Cervical adenocarcinoma seems to 
have an added tendency to spread beyond the pelvis. 47 
For carcinoma of the cervix in general there is a lev-
elling off in mortality after 2 years and by 3 years 
for irradiated squamous carcinomas, 94% of pelvic re-
currences will have occurrect. 48 , 49 By 7 years the sur-
vival rate is equivalent to that of the general popula-
tion.48 Distant metastases occurred in 21% of squamous 
carcinomas in a large series treated by radiotherapy.49 
With better control of the disease in the treated area, 
more patients will show evidence of disseminated cancer 
because of their longer survival. There are compli-
cations of treatment by radiotherapy or by surgery with 
some evidence that radiotherapy complications are more 
serious. 83 Sexual function following surgical therapy 
may furthermore be significantly better. 50 
There is evidence that in certain Western coun-
tries there has been a significant increase in the in-
cidence of preinvasi ve carcinoma of the cervix during 
the time period 1960 to 1980. 51 , 52 Furthermore, the 
overall rate of decrease in invasive carcinoma appears 
to be levelling off and an actual increase has been ev-
ident in younger women. 52 , 55 , 56 With continuing 
follow-up of these women it becomes clear that a cohort 
effect is present and the increased incidence will 
spread to the older age groups with time. 52, 53, 56, 57 
· The increased incidence · of invasive carcinoma of the 
cervix in the young in the United Kingdom, the United 
States, Australia and New Zealand has been of the order 
of twofold or more.55,56 
Evidence of the effectiveness of screening for 
preinvasive cervical carcinoma is available from a num-
ber of countries.52 In those patients who develop car-
cinoma of the cervix there is a disturbing lack of uti-
lization of the available screening services.54 
5 
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1.2 HUMAN PAPILLOMAVIRUS INFECTION 
The Human Papillomavirus (HPV or Wart Virus) is cur-
rently the object of much interest as a possible aetio-
logical agent in cervical carcinoma. 9 , 10 At present it 
is felt to be the most important single factor in the 
multifactorial genesis of the disease.11,12,13 
The papillomaviruses belong to the Papovaviridae 
family, together with the polyoma ( or SV40) viruses, 
and are a deoxyribonucleic acid (DNA) virus. The DNA 
occurs in a double-stranded circle and there is a 72 
capsomere icosahedral protein shell. The papil-
lomaviruses infect both man and a variety of animals, 
e.g. the cow and the rabbit, and induce epithelial pro-
liferations.13 
The papillomaviruses show marked heterogeneity as 
well as remarkable host specificity. There are cur-
rently well over 50 types of human papillomavirus as 
detected by DNA hybridizations, with each new papil-
lomavirus designated a different type if it shares less 
than 50% sequence homology with any other. 15 (There 
are, however, antigens common to the entire genus. ) 
Host specificity is illustrated in the human by the 
fact that Type 1 is found in the common deep plantar 
wart, Type 2 in the common hand wart and yet other 
types in the genitalia. Types 6 and 11 make up 90% of 
genital HPV infection al though 15 of the viral types 
can infect the genitalia. Certain of the latter 
viruses have an enhanced oncogenic potential, in that 
they are regularly found incorporated in the DNA of 
cervical carcinomas. They include the virus Types 16 
and 18, and, less commonly, 31, 33 and 35.12-14 
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Although the epidemiological evidence demonstrates 
a sexually transmitted agent in the aetiology of cervi-
cal cancer · (which currently is felt to be HPV by 
exclusion of the other contenders) and although the 5 
types mentioned above are regularly incorporated into 
cervical carcinoma DNA, and although malignant trans-
formation occurs commonly in bovine and rabbit papil-
lomavirus infections, there is not yet adequate evi-
dence that HPV infection in humans causes malignant 
transformation. 9 ,11-13 (It can be shown, for example, 
that HPV 16 is also found in the normal cervix. 9 ) It 
may be postulated that there is intracellular control 
of incorporated HPV DNA ex~ression by cellular genes, 
in which case malignant transformation is viewed as a 
failing host cell control of persisting viral genes. 
Factors modifying cellular gene function might then 
initiate the malignant transformation which is promoted 
by the HPV infection - the classic Zur Hausen hypothe-
sis.12 The initiating events are at present thought to 
be multifactorial and poorly defined, but certainly in-
clude cigarette smoking. 
Compromised immune state plays a major role in HPV 
infection in the cervix and leads to a very high 
incidence of cervical intraepithelial neoplasia.35 
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Almost all cervical carcinomas are found to con-
tain incorporated papillomavirus DNA (typically 90%10) 
if subjected to DNA extraction and molecular cloning, 
with subsequent DNA hybridization analysis. This tech-
nique can also be performed in situ on paraffin-embed-
ded biopsies or cytological specimens . 18 , 20 With the 
recent advent of the polymerase chain, reaction ( PCR) , 
which is a technique to amplify the target DNA se-
quence, this figure of 90% should improve still fur-
ther.14 There should also be more adequate demonstra-
tion of the .ubiquity and type of papillomavirus infec-
tion in the female genital tract in general than is 
possible with current techniques such as cytology and 
histology which already show an up to 80% synchronous 
HPV infection rate for cervical-vulval or vulva-cervi-
cal papillomavirus lesions.16 
Besides the definitive but highly complex DNA 
hybridization techniques, evidence of HPV infection can 
be obtained by immunocytochemistry, electron mi-
croscopy, cytology, serology, colposcopy and 
histology.10,13,18-21 
Colposcopy probably has a similar (poor) 
sensitivity to that of cytology. One study calculated 
a sensitivity of 35%.21 Serology is of no value in 
genital papillomavirus infection because the 
concentration of virus particles is extremely low .13 
Electron microscopy is said to show a sensitivity 
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better than that for conventional histology, but is a 
complex procedure .18 Immunocytochemistry for papil-
lomavirus group-specific capsid antigens with a 
peroxidase-antiperoxidase procedure is well des-
cribed. lO The frequency of localization of antigens 
diminishes in relation to the severity of the lesion 
and none are found in cases of carcinoma. The assembly 
of virions within the nucleus is linked to the 
maturation of the squamous cell. The sensi ti vi ty of 
immunocytochemistry seems relatively poorer than that 
of histology in the more severe lesions.18 
cytology has been widely used to detect HPV infec-
tion. There is a 1 to 2% HPV infection rate in routine 
cervical cytology.20 The cytological features are well 
described and confirmed by studies using other modali-
ties for HPV detection. Features include koilocytosis 
(perinuclear cytoplasmic vacuolation), binucleation, 
degenerative nuclear changes, dyskeratosis and in-
creased density of the peripheral cytoplasm. lo, 20 A 
number of studies comparing cytology to DNA hybridiza-
tion techniques show that cytology has a good speci-
ficity but a poor sensitivity in detecting HPV 
infection. 19- 21 Typically the sensitivity is in the 
region of 40% of that achieved by DNA studies. There 
is evidence, as with immunocytochemistry, of a 
declining ability to detect HPV infection as the lesion 
becomes more severe.lo 
Histology suffers from the same decline in HPV de-
tection rate as the lesion approaches malignancy. Fig-
ures from a series of 500 biopsies showing CIN give an 
HPV detection rate of 80% for CINI versus 63% for CIN 
III.lo In another study by Sato et a1l 8 figures were 
89% and · 20% with an average of 66%. In this latter 
study DNA hybridization showed an overall 98% detection 
rate. In a study of 98 cases of CIN by McNicol et a121 
histology anq DNA hybridization proved equally sensi-
tive in detecting HPV infection ( 80 versus 81% over-
all). Histology is not useful for detecting HPV in ma-
lignant tissue. _ 
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The histological features of HPV infection, which 
were first reported by Meisels and Fortin in 1976 and 
were not widely taught until the early 1980's, are ex-
tensive and well described. · They include koilocytosis, 
nuclear wrinkling, binucleation, multinucleation, dys-
keratosis, prominent metaplastic parabasal cells and 
epithelial spikes.10,18 
1.3 CARCINOMA OF THE CERVIX IN YOUNG WOMEN 
The mean age, at diagnosis, of the patient with inva-
sive carcinoma of the cervix depends on the sample 
analysed. The same applies to any breakdown of the age 
distribution of the disease. In a large, population 
based study of 10,022 cases of invasive carcinoma in 
the United Kingdom ( 10% of all cases in England and 
Wales) covering the years 1957 to 198159 , the age dis-
tribution was as follows: 
Under 20 
Under 35 
75 and over 
Peak incidence 
6 cases, i;e. 0,06% 
7,8% 
8,3% 
age group 55 - 59 
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Older figures for the United States 1914-194660 
based on 4 652 patients and corrected for the female 
population of the state of New York give the following 
age distribution for invasive carcinoma of the cervix: 
Under 20 0,05% 
Under 35 





Many hospital-based studies have been done on the 
younger patient group. By convention these have been 
the under . 35 group, al though some have used under 30 
groups and others under 40 groups. The under 35 group-
ing seems to have the most merit, as the incidence of 
the disease is still rising rapidly at this point while 
at the same time sufficient numbers are obtained for 
analysis and a patient under the age of 35 years is 
s:till clearly young. The group of under 20 patients 
forms a special group of rarities of the case report 
type. 
As discussed in section 1.1 of the Introduction, 
the incidence of invasive cervical carcinoma has in-
creased in certain Western countries in the young age 
group. This is clearly seen in age distribution stud-
ies done over time, although these figures are often 
skewed by referral patterns in hospital-based studies. 
In the British population-based study of Meanwell et al 
the under 35 year group in 1965 had 13 cases; in 1975 
there were 13 and in 1980 there were 6459. Because of 
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a falling incidence in older women there is no obvious 
overall increase in the incidence of invasive carcinoma 
of the cervix in the United Kingdom. A hospital-based 
study in the west of Scotland found that the number of 
patients under 35 referred to them doubled between 1974 
and 1984 61 . In Brighton the mean age of referred 
patients with cervical cancer fell from 50 years in 
1967 to 35 years in 1977. 6 2 In a study of 385 new 
patients at the Royal Marsaen hospital the number of 
patients less than or equal to 35 years of age rose 
from 2% for the triennium 1970-1972 to 18% for 1982-
1984. 63 Of 1 451 patients seen at the Mayo Clinic from 
1940-1949, 11,6% were 35 years of age or younger.64 
As mentioned earlier, invasive carcinoma of the 
cervix in those below 20 years of age must be classed 
as exceedingly rare. There have been a number of re-
views of this subject with a review in 1968 finding 
only 32 cases in girls under the age of 17 in the world 
literature since 1888.65,66,67 A review by Dekel et 
a1 67 in 1982 found only 11 cases of squamous carcinoma 
in the age group under 20 in the world literature for 
this century. 
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Quite apart from the issue of a rising incidence 
of cervical cancer in young women is the empirical ob-
servation that the mortality for this group has risen 
markedly. Yule in 1978 showed that while the overall 
mortality had decreased in England and. Wales by 11,8%, 
the mortality in the group under 35 had doubled in the 
6 years 1970 to 197668. Green in New Zealand 
demonstrated a similar doubling of the mortality for 
this group (1941-1974), in the face of an overall 
marked decline in mortality rates55. 
The reason for these changes is unknown.33,69 The 
main debate revolves around the issue of whether there 
has been a fundamental change in the nature of cervical 
carcinoma or whether the increased mortality is 
explainable purely on the grounds of an increased inci-
dence of the disease; and if . the latter holds true 
what then the cause of the increased incidence is. 41 
This has become a major issue in cervical carcinoma, 
with enormous implications for screening and treatment 
of the disease as well as for understanding its funda-
mental aetiology. The issue is compounded by the pos-
sibility of smaller but simultaneous changes in both 
the nature and incidence of the disease. 
Numerous studies have been done to determine if 
there is less survival, in the young group, i.e. a more 
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virulent disease, and there is considerable evidence 
that this may indeed be so. 24 , 70-79 Evidence for an 
increase, in the young group, of the prognostic 
variables associated with a poorer prognosis is as 
follows: more non-squamous tumour types; more poorly 
differentiated ( high grade) tumours; more cases of a 
short preinvasive phase; more recurrent disease; more 
lymph node metastases; more false negative cervical 
cytology screening; and a longer delay in making the 
diagnosis.24,40,61,64,70,72-75,86,88,96 There is how-
ever no evidence that the young group avails itself 
less of screening cytology services or presents with 
later stage disease.69 Indeed, there is a large body 
of evidence to show that the disease is found at an 
earlier stage in the younger group.61,63,81,82,85,92,95 
There is no obvious explanation for this latter common 
finding. There are also no studies in the literature 
comparing human papillomavirus (HPV) infection rates or 
types in young versus older patients with invasive 
cervical carcinoma. 
The undoubted fact of an increased number of 
deaths from carcinoma of the cervix in the younger age 
group has been shown, in contrast to the above quoted 
evidence, to be unrelated to a decreased survival in 
the young in an impressive number of studies spanning 
most of this century.27,37,39,40,48,59,61,63,64,81-95. 
The increased deaths relate rather to an increased 
incidence of the disease. 
The consensus of opinion of major reviews of the 
problem is that Age is a prognostic factor of uncertain 
significance.33 
The role of HPV infection in any shift in disease 
virulence, should this be present, or in a relative 
increase in incidence in the younger group is unex-
plored. 
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The death of a young woman from carcinoma of the 
cervix makes.a strong impression on her medical atten-
dants and there is a feeling, from personal experience, 
amongst many workers in the field that there may indeed 
be an issue of decreased survival in younger women.22 
1.4 STUDY OBJECTIVES 
The aim of the study, as stated in the official proto-
col, is as follows: "To obtain objective information 
on the natural history of invasive carcinoma of the 
cervix in women under 35 years of age and to compare it 
to the disease in women aged 35 years and older to see 
if there are any significant differences". 
Aspects of the natural history of carcinoma of the 
cervix in each of the two groups considered important 
for comparison are as follows: 
(a) Survival; 
(b) Miscellaneous Patient Characteristics, e.g. Race, 
Parity, Pregnancy State. 
(c) Prognostic Factors: 
- Disease Stage 
Tumour Size 
- Tumour Geographical site 
- Tumour Grade 
- Tumour Type 
Lymph Node Involvement 
- Recurrence Time and Site 
- Length of the Preinvasive Phase 
- False Negative Cytology 
(d) Treatment Type and Complications 
(e) Evidence of Human Papillomavirus Infection 
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It is planned to study these issues in a scientif-
ically valid way, within the resources of a single in-
vestigator engaged also in full-time clinical work, so 
that clear conclusions can be reached on the matter of 
whether or not a difference exists between cervical 
carcinoma in young versus older women. 
A secondary goal will be to use the data to check 
for any change in the relative proportions of young and 
older patients to see if there is evidence of an in-
creased incidence in younger women locally, in keeping 
with the findings in Western nations. 
In view of the epidemiological nature of the data 
under investigation - which precludes the experimental 
approach97,99 - the overall study design chosen is ob-
17 
servational, with an unbiased comparison of the 
previously mentioned aspects being made between a group 
of young patients with the disease and a group of older 
controls with the disease, ensuring that the two groups 
are fully comparable. 97 , 99 In order to study the 
natural history of the disease this comparison is a 
follow-up or cohort study. 98 , 99 As i~ would be beyond 
the resources of the study to institute follow-up over 
1 O years or more concurrent with real time, the wel 1 
described non-concurrent prospective format is chosen, 
allowing analysis of recorded data.98,99 
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2. MATERIALS AND METHODS 
2.1 RESOURCES 
The treatment of invasive carcinoma of the cervix is 
highly complex and in general involves radiotherapy or 
radical surgery or a combination of both. The result 
of this complexity is that treatment is centralized to 
special centres based in large hospitals. In the city 
of Cape Town there are two such treatment centres, each 
based at an academic teaching hospital group, i.e. 
Groote Schuur Hospital and Tygerberg Hospital. 
The two teaching hospitals are ref err al centres 
for a large, poorly defined section of the Cape 
Province. They are either natural referral centres for 
country areas to which they are in closest geographical 
proximity or special referral centres for some of the 
treatment centres with lesser facilities. The closest 
treatment centre to Cape Town is found in Port 
Elizabeth. 
Radical pelvic surgery is seldom performed in 
private and if so is invariably done by a senior 
gynaecologist associated with a teaching hospital. 
The department of radiotherapy issues a radiother-
apy number to every patient with a malignant tumour 
registered by any of its clinics. This applies even if 
the treatment of the tumour has been purely surgical. 
About 3000 numbers are allocated per year. Numbers are 
allocated at registration on a daily basis, for the en-
tire radiotherapy division on a first come first served 
principle. 
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All cases of invasive cervical cancer at Groote 
Schuur Hospital are registered and assessed by a com-
bined assessment clinic (CAC) consisting of both Gynae-
cological Radiotherapists and Gynaecological Oncolo-
gists, in close association with a Gynaecological 
Pathologist. All staging is by combined decision and 
the same applies to treatment recommendations. The 
details of each case are fully recorded and include 
comprehensive follow-up notes. The gynaecological CAC 
makes use of a special summary control sheet (See 
figure 2) for follow-up purposes. The patients's home 
address is also entered on the form. 
Follow-up of patients i~ usually on a lifetime ba-
sis. A few patients are discharged if they have 
survived 10 or more years but in general this is not 
policy and such patients return for checkups every two 
years. 
In all cases, when a given follow-up appointment 
is missed there is a routine mechanism for pursuit of 
the matter. In almost all cases an explanation is 
obtained and entered in the records and if the patient 
is still alive further follow-up arrangements are made. 
Certain country cases, especially those who live 
more than a day's journey to and from Groote Schuur 
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Hospital have follow-up done locally. Their control 
sheets are periodically updated by letters of enquiry. 
These records have been regularly computerized 
since 1982. 
All cases of cervical carcinoma have a histopatho-
logical diagnosis, with the specimen usually taken by 
punch biopsy of an obvious clinical lesion. The his-
tology report may not always have originated at Groote 
Schuur Hospital. 
The department of pathology stores all slides of 
malignant tumours which it has processed in its 
archives and these can be recovered if the relevant 
histology numbers are known. A screening cytology 
laboratory also forms part of the gynaecology oncology 
service. 
The cytology service also stores its abnormal 
slides which can be located by cytology number and 
year. 
During the earlier part of the study (1974 to 
1979) the Department of Radiotherapy used a modified 
(higher dose) form of radical radiotherapy as part of a 
British Medical Research Council trial in some of the 
patients allocated for radiotherapy. This protocol 
did, however, result in a higher incidence of radiation 
bowel injury and was ultimately abandoned. 
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2.2 DATA SELECTION 
As mortality in young women has at least doubled in the 
West {See section 1.3), it is felt that a study with 
80% power to detect a 50% difference in survival at the 
95% confidence level will be adequate to allow a 
clinically meaningful conclusion. 100 
The Gynaecological CAC registered approximately 
150 cases of carcinoma of the cervix per year during 
1974 - 1983. To achieve an adequate number of young 
patients it was decided that a 10-year study would be 
required. This was based on the following reasoning 
and calculations. 
A type II error is likely to be the limiting fac-
tor in any comparison with older patients using limited 
numbers ( if a is chosen as o, 05 and B as o, 20 as is 
usually done) 98 ,lOl. 
For the most important comparison, namely sur-
vival, the value pc (or the_ probability of survival in 
the controls) is chosen as o, 5 (i.e. 50% 5-year sur-
vival; see Section 1.1). The minimum difference to be 
detected is 50% (see Section 1.4) which translates into 
a factor 0,5x(l-0,5) or 0,25. A value pE ( i . e. the 
probability in the test group at the given difference) 
is then calculated as pE = pc + clinically important 
difference or pE = 0,5 + 0,25 or 0,75. From the value 
pE = 0,75 a graph can be used to determine study power 
at various sample sizes. If 80% power is chosen for 
this calculation a sample size of 70 is required.loo A 
10-year study is expected to yield 1,500 patients of 
whom ±7.5% at least (see Section 1.3) should be under 
the age of 3 5 years . This gives 112 patients, thus 
allowing some leeway for study losses. A 5-year study 
(66 patients) would yield too few patients. 
It was decided furthermore that the study group or 
"cases" should include if possible all young patients 
over the 10-year period. 
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As the data collection and analysis began on 1 
January 1989, the follow-up part of the study was ended 
on 31 December 1988. To allow the possibility of at 
least a 5-year follow-up on all cases for survival 
curves, the 10 year period selected for study became 
1974 to 1983 inclusive. 
In view of the overall design strategy, which is 
an unbiased comparison of a cohort of younger women 
with a cohort of older women (see Section 1.4), these-
lection of the older women or control group next re-
quired attention. Both groups need to be fully compa-
rable. 
The possibility of analysing the entire older 
group, i.e. about 1400 patients (or 1500-112) could not 
be entertained due to the limited resources of the 
study. The alternative method, i.e. that of a random 
sample of the control group, was therefore used. For 
ease of comparison a sample size equal in size to that 
of the study group (or young cases) was decided upon. 
To achieve this and at the same time make an unbiased 
or random selection from the older group the following 
method was used: for each radiotherapy number of a 
Figure 1: Gynaecological CAC Follow-up Control Sheet. 
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young patient a further radiotherapy number from cases 
of carcinoma of the cervix was selected which was the 
next highest number and did not in itself belong to an-
other young patient. Seeing that radiotherapy number 
allocation is a stochastic procedure, this method al-
lows a random sampling of older women. This method has 
been used in other similar studies of the problem. 95 
The selection of cases and controls was done manu-
ally and was facilitated by the existence of the Fol-
low-up Control Sheets (see Figure 1). Once selected, 
the patients' radiotherapy f elders and, if necessary, 
the hospital folders were drawn and further examined. 
Two facts became evident at this stage. Firstly, 
the proportion of younger women was greater than that 
expected for population studies (see Section 1.3) and 
secondly, a number of biasing factors were potentially 
present. These factors related either to the unfair 
weighting of one group against the other or to an in-
valid assessment of survival in carcinoma of the 
cervix. A total of 11 exclusion criteria were devel-
oped, details of which appear in Section 2. 3 and pa-
tients were only selected for each group if these did 
not apply, i.e. if they were eligible. The exclusion 
criteria were 
trols. Thus 
applied equally to both cases and con-
the study included all eligible young 
women, with the controls being a random sample of the 
Figure 2: Data Record Sheet 
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next highest eligible radiotherapy number as described 
above. 
To be eligible for the study each patient from ei-
ther group had to have newly diagnosed, properly 
staged, invasive carcinoma of the cervix in an intact 
uterus. The patient had to accept treatment and be 
free of a second primary carcinoma. The histology on 
which the diagnosis was based had to have been pro-
cessed by the local Groote Schuur Pathology Department 
and the patient had to have her permanent home address 
(domicile) in an area which made Groote Schuur Hospital 
the normal first point of referral. Any specially re-
ferred cases within this area were also not eligible. 
By confining the study to the geographically associated 
population it was hoped to make the data on the study 
groups generalizable.102 
In this way the total number . of eligible cases 
amounted to 82. This was balanced by a random sample 
of 82 eligible controls. The cases and controls were 
not matched or pre-stratified in any further way. 
Data collection on each patient was in keeping 
with the study objectives outlined in Section 1.4. A 
standardized form (Figure 2) was drawn up and used to 
record the data from each case. This data was coded 
into numerical form to allow computer processing if 
necessary. 
Figure 3: Histology data sheet. 
- 4li ,.. - n • 
'-'OSF ITAL ST I Ct<.EF' 
~UCIN STAIN USED 
NOF'MAL ~DJ~CENT EFITHELIUM 
EV I [•ENCE oJF HFV 
Figure 4: Cytology data sheet. 
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Part of the data collected from the folder was the 
histology number in every case. This was then sup-
plied, in the form of a further data sheet (Figure 3) 
to the Department of Pathology where the relevant 
archival slides were drawn and reviewed by a single, 
blinded, gynaecological histopathologist (Professor A J 
Til tman) . Apart from the data displayed, the tumour 
grade and type were also recorded. 
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Similarly, a cytology sheet was supplied to the 
Cytology Laboratory for each case (Figure 4). Cytology 
numbers were not available for each case as a lack of 
Groote Schuur cytology was not an exclusion criterion 
for the study. Because a great many of the cytology 
results were reports from other laboratories, the 
cytology results are as reported and not based on a 
review (except for the search for HPV on Groote Schuur 
· slides). This search was conducted by a single, 
blinded senior technologist. 
The date of registration of the patient with the 
CAC was taken as the date of entry into the study. The 
only exceptions were cases of retrospective registra-
tion of greater than one month's delay following treat-
ment. This applied to a few cases of radical hysterec-
tomy that were registered post-operatively to facili-
tate speed of treatment. In these few cases (<5) the 
date of entry into the study was taken as the date of 
operation. 
The · key to the data sheet ( Figure 2) is as fol-
lows: 
Question 1. Case or Control 
1 = Case 
2 = Control 
This is self-explanatory and makes for ease of ., 
analysis. 
Question 2. Age at Diagnosis 
1 = 30 - 34 
2 = 20 - 29 
3 = <20 
4 = 35 - 49 
5 = 50 - 75 
6 = >70 
The actual age of each patient was also entered. 
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The correctness of the age was checked both against the 
hospital registration details and the CAC proceedings. 
Question 3. Race 
2 = European 
4 = Coloured 
6 = Asian 
8 = Black 
This numerical code matches that of the Hospital. 
Although race independent of other factors is not 
considered to be of importance in cervical carcinoma 
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(see Section 1.1), a difference in proportions between 
the two groups might indicate that a new factor is 
present in one of the racial groups. 
Question 4. Parity 
The number equals the actual parity. 
Parity was chosen rather than gravidity as estima-
tion of the latter by patients is clearly less 
reliable. Although parity is not thought to relate to 
prognosis (see Section 1.1), determination of the par-
ity of a modern young cohort of patients with cervical 
carcinoma is considered to be relevant. Are they still 
of high parity as in the case of their classic counter-
parts? 
Question 5. Pregnancy Status at Diagnosis 
1 = Non-pregnant by at least 6 months 
2 = Pregnant, or within 6 months of delivery 
Pregnancy is not felt to be a prognostic factor 
although some dispute this (see Section 1.1). The time 
limit after pregnancy for inclusion in the pregnancy 
group varies in the literature, typically from 3 months 
to 12 months . Six months was therefore chosen as a 
compromise. It was decided to include this factor to 
see if pregnancy is a particularly common or uncommon 
event in this particular study group as the factor may 
be controversial. 
Question 6. Tumour Stage 
1 = lB 
2 = 2A 
3 = 2B 
4 = 3 
5 = 4A (Bladder or Rectum) 
6 = 4B (Distant) 
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Only an official multi-parity FIGO staging by the 
CAC was accepted as valid . 106 Microinvasive disease 
(Stage lA) was not included, nor was any type of post-
surgical staging. If positive lymph nodes were found 
at an attempted radical hysterectomy the case was in-
cluded under its original clinical stage, i.e. usually 
stage lB. Stage 3 disease was not differentiated fur-
ther into A or B as there were no cases of stage 3A 
that were not also stage 3B: 
Question 7. Tumour Volume 
1 =Clearly> 3 cm diameter 
2 =Clearly< 3 cm diameter 
3 = Unclear 
There is no clarity yet in the literature on this 
topic beyond the fact that large size is a bad prognos-
tic factor (see Section 1.1). There is no consensus on 
the exact method of measuring the tumour. Usually di-
ameter is measured and not volume. In this study, di-
ameter was estimated from the tumour description in the 
CAC notes. Often this was clear, especially that it 
was larger than 3 cm. As the study and control groups 
were subjected to the same estimation process, the re-
sults are felt to be comparable. 
Question 8. Mode of Treatment 
1 = Radical Radiotherapy 
2 = Radical Radiotherapy following Surgery 
3 = Radical Radiotherapy plus Salvage Hysterectomy 
4 = Palliative Radiotherapy 
5 = Palliative Radiotherapy and Defunctioning 
Surgery 
6 = Palliative Radiotherapy and Chemotherapy 
7 = Radical Surgery 
8 = Radical Surgery and Adjuvant Chemotherapy 
9 = Palliative Surgery 
o = Nil. Patient Terminal. 
29 
The purpose of this long list of permutations is 
to identify those in each group that were not treated 
with curative intent. If all other factors are equal, 
patients treated with radical radiotherapy and radical 
surgery should have an equal survival rate (see Section 
1.1) . Factors such as failed surgery, salvage hys-
terectomy, chemotherapy and adjuvant chemotherapy are 
of interest to document al though the numbers in the 
study will be very small. 
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Question 9. Lymph Node Status at Primary Surgery 
1 = Negative 
2 = Positive 
O = Not Applicable (i.e. no primary surgery) 
The proportion of patients with positive lymph 
nodes at surgery is well known in the literature. Is 
the young group at any special ri~k as has been 
suggested? (see Section 1.3) 
Question 10. Major Late Complications of Primary 
Treatment (After 1 year) 
1 = None 
2 = Required bowel surgery due to radiotherapy 
3 = Required urinary diversion due to radiotherapy 
4 = Required urological surgery due to radical 
surgery 
5 = Permanent urological injury due to surgery 
6 = Chronic lymphocyst formation 
7 = Death 
8 = Significant other (by name) 
9 = Residual tumour or recurrence within 1 year 
O = Unknown due to poor follow-up 
Significant treatment complications might have a 
more serious impact in the younger patient who would be 
expected to live on for a longer time if cured. Long 
term survival studies show that after between 7 _and 10 
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years the survival of patients with treated cervical 
carcinoma is the same as that of the general popula-
tion.48 
Question 11. Time to Confirmed Recurrence 
The number equals the time in months from CAC reg-
istration tti confirmation of tumour recurrence at the 
official follow-up clinic. Part of a month greater 
than 15 days was recorded as a month, while 15 days or 
less was not counted. Confirmation of recurrence was 
seldom based on histology in practice and was usually a 
clinical assessment. The recorded judgement of the at-
tending doctor that recurrence had occurred -was taken 
as confirmation (i.e. time was not measured from voiced 
patient suspicions or vague symptoms). 
O = No recurrence or no follow-up 
1 = Residual tumour present 
To determine recurrence sites and times accurately 
one also has to know the follow-up status of each 
group. 
Question 12. Site of Recurrence 
1 = Contiguous 
2 = Non-contiguous 
3 = Both 
4 = Not applicable (no recurrence or unknown) 
Contiguous encompasses the entities of local, cen-
tral, pelvic or regional recurrence and is best defined 
by its alternative, non-contiguous. 
equivalent to distant metastases. 
The latter is 
This includes in-
guinal lymph nodes, malignant ascites, bony destruction 
or nodular enlarged liver and any more peripheral mani-
festations. 
Question 13. Recurrent Tumour Type 
1 = Squamous carcinoma 
2 = Adenocarcinoma 
3 = Ade no squamous carcinoma 
4 = Other (as stated) 
5 = Not biopsied - histology unknown 
0 = Not applicable (no recurrence or no follow-up) 
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This section was included in an attempt to see if 
certain tumour types recurred more often. 
Question 14. Mode of Treatment of Recurrence 
0 = Not applicable (no recurrence or no 
1 = Radical radiotherapy 
2 = Chemotherapy alone 
3 = Nil 
4 = Palliative surgery 
5 = Exenteration 
6 = Full irradiation at a distant site 
7 = Palliative radiotherapy 
follow-up 
The purpose of this section is to check if there 
is a difference in intensity of treatment of recurrent 
disease between the young and the older groups. 
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Question 15. Tumour Status at Death 
0 = Definitely alive 
1 = Died of ca. cervix, contiguous only 
2 = Died of another cause, no ca. cervix present 
3 = Died of another cause, ca. cervix present 
4 = Died of ca. cervix, non-contiguous only 
5 = Died of ca. cervix, contiguous and 
non-contiguous 
6 = Definitely dead from ca. cervix, site 
uncertain 
7 = Condition unknown, i.e. may be alive 
This provides data on death from unrelated disease 
and loss to follow-up as well as giving further infor-
mation on tumour site in the two groups. 
Question 16. Direct Cause of Death 
1 = Haemorrhage 
2 = Sepsis 
3 = Uraemia 
4 = Other 
5 = Died in unknown way 
O = Not applicable (alivi or lost to follow-up) 
What are the direct causes of death ·and are they 
any different between the two groups? 
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Question 17. Ten-year Records Status 
1 = Not available 
2 = Available 
This section was included for ease of analysis in 
the event of a late or long-term study using this data, 
e.g. a study of proportional changes betweeri two con-
secutive 5-year groupings (i.e. 1974-1978, 1979-1983). 
Question 18. Known Survival Time 
The number given is the time in months from date of en-
try into the study to the date of death, loss to fol-
low-up, intercurrent death of known alive status at the 
conclusion of the study on 31 December 1988. Fractions 
of -months are ignored if less than 16 days and counted 
as 1 if greater than 15 days. The actual date of the 
event, i.e. one of the four possibilities mentioned 




This is the data required to 
curve of the Kaplan-Meier 
The handling of the data at the conclusion of the 
study requires comment. Many patients who are not 
dead, lost or dead from interaurrent disease will have 
had their last follow-up visit some time prior to the 
31 December 1988 cut-off date, making their status on 
that date not accurately known. To avoid this problem 
two mechanisms were used: firstly, because the data 
collection took place through most of 1989 and most of 
the patients had a follow-up visit in 1989, their 
status on 31 December 1988 could be retrospectively 
determined. Secondly, in those few patients who did 
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not have a follow-up appointment in 1989, there were 
patients with a previously perfect follow-up record 
(see Question 19). These patients were assumed to be 
alive on 31/12/1988 if the time for their next ap-
pointment had not yet come e.g. was due in early 1990. 
Patients with poor follow-up, on the other hand, were 
presumed lost on their last follow-up appointment prior 
to 31/12/1988. 
Question 19. Follow-up Status 
1 = No default 
2 =Defaulted< 3 months 
3 =Defaulted> 3 months but status known 
4 = No follow-up 
Patients often attend follow-up for a while and 
then default, although their ultimate status remains 
known (by telephone, letter or other reports). Follow-
up is thus comprehensive (1 + 2), crude (3) or non-
existent (4). 
Question 20. Endocervical Tumour Clinically 
1 = No 
2 = Yes 
A tumour predominantly in the endocervical geo-
graphical site might have a greater tendency to be 
clinically understaged or to be an adenocarcinoma, both 
of which may have an effect on survival (see Section 
1.1). The purpose of this section is to check if there 
is a different distribution of endocervical tumours in 
the two groups. 
Question 21. Mucin stain Status 
1 = Not used 
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2 = Used 
There are claims in the literature that if mucin 
staining is not done routinely then for every 
adenosquamous tumour diagnosed two are missed. 24 As 
mucin production may be associated with · a poorer 
prognosis, especially in younger patients, it was felt 
worthwhile to document the actual use of mucin stains 
during 1974-1983 in the two groups (mucin stains have 
been done routinely at Groote Schuur Hospital since 
1989). 
Question 22. Recurrent Tumour Type Correspondence 
1 = Corresponds 
2 = Not the same as the original 
3 = Unknown (no biopsy) 
4 = Not applicable (no recurrence or no follow-up) 
The purpose of this section corresponds with the 
previous question, i.e. in the light of further 
histology was there any error in the original his-
tology? What is the distribution of these errors in 
the two groups? 
Question 23. Tumour Differentiation/Grade 
1 = Grade I 
2 = Grade II 
3 = Grade III 
Tumour grade, of which differentiation is only 
part of the assessment32, is felt by many to be of 
prognostic importance (see Section 1.1). 
grade distribution between the two groups? 
Question 24. Tumour Type 
1 = Squamous carcinoma 
2 = Adenocarcinoma 
3 = Adenosquamous carcinoma . 
4 Other (specify) 
What is the 
Tumour type is thought by many to be of prognostic 
importance (see Section 1.1). A great many cell types 
have been described, some of which are extremely rare. 
This section makes use of a simple, everyday classifi-
cation of clinical importance. 
Question 25. Angiolymphatic Permeation Status 
1 = Not commented on 
2 = Definitely present 
3 = Definitely not present 
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Angiolymphatic permeation or "channel invasion" is 
probably equivalent to lymphatic micrometastases and as 
such is of prognostic importance (see Section 1.1). To 
assess a specimen for this feature one requires more 
than a cervical punch biopsy. 
Question 26. Adjacent Non-neoplastic Epithelium Status 
1 = Not present 
2 = Present 
The accuracy of ~istological assessment of the 
presence or absence of HPV infection is inversely 
related to the d_egree of neoplasia and to be truly 
accurate requires non-neoplastic epithelium (see 
Section 1.3). This section controls for this variable 
in the two groups. 
Question 27. HPV Status on Histology 
1 = Not present 
2 = Present 
If there was any doubt whether HPV was present or 
not it was recorded as not present. The presence of 
HPV was only recognised by histological means in 1976 
( see Section 1. 3) and was not regularly reported at 
Groote Schuur until the early 1980's. Thus re-
examination of the archival histology for HPV provides 
new data. 
Question 28. Cytology Abnormal Result Distant from 
Diagnosis · 
1 =CINI 
2 = CIN II 
3 = CIN III plus adenocarcinoma-in-situ 
4 = Possible microinvasive carcinoma 
5 = CIN III plus severe endocervical atypia 
6 = CIN III only 
7 = Severe endocervical atypia (only) 
8 = Adenocarcinoma-in-situ 
9 = Negative cytology 
O = No previous cytology 
These results were at least 3 months prior to the 
diagnosis of malignancy. They represent the most 
distant result known if there are more than two 
abnormal results. This section has the purpose of 
seeing how many preinvasi ve lesions escaped adequate 
management or were possibly false negative for 
malignancy in each group. 
Question 29. cytology Result at Diagnosis 
1 = Invasive carcinoma (squamous) 
2 = Microinvasive carcinoma (squamous) 
3 = CIN I or II 
4 = Adenocarcinoma 
5 = Severe endocervical atypia only 
6 = CIN III 
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7 = CIN III plus adenocarcinoma-in-situ 
8 = CIN III plus severe endocervical atypia 
9 = Negative cytology 
O = Cytology not done 
These were results at the time of registration 
with the CAC for cervical carcinoma and up to 3 months 
prior to this. The purpose of this section is to see 
how many smears were falsely negative in each group. 
Question 30. Complete cytology Status 
1 = Complete by not more than 1 year 
2 = Complete by not more than 3 years 
3 = Complete by not more than 5 years 
4 = Totally incomplete at 5 years 
5 = Partly incomplete 
By complete is meant a negative result at a date ( as 
given in years) prior to an abnormality being found. 
This gives an indication of the longest possible time a 
lesion could have been present prior to registration 
with the CAC and gives a measurement of the speed of 
progression of the tumour, i.e. length of the pre-inva-
sive phase. Totally incomplete cytology in this 
context means no cytology baseline in the last 5 years. 
Partly incomplete means that only a previous abnormal 
result is known. This section analyses the screening 
adequacy of patients who develop cervical carcinoma. 
Question 31. Length of Known Pre-invasive Phase 
The number given is the time in months from the date of 
the last normal cytology result to the date of regis-
tration with the CAC or invasive cytology date (if ear-
lier). This gives the longest time the pre-invasive 
phase could possibly have been (excepting false nega-
tive cytology). Is the preinvasive phase shorter in 
young women? 
Question 32. HPV Status on Cytology 
1 = Not present on reviewed slide 
2 = Present on reviewed slide 
3 = Cytology by report only 
4 = No cytology from any source 
HPV can be detected by cytology (see Section 1.3). 
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This has been routinely reported only since about 1983 
and is therefore new data on the reviewed slides. cy-
tology numbers, as gleaned from various reports in 
folders, are not unique to the Groote Schuur labora-
tory, making the exact retrieval rate of archival mate-
rial difficult to determine. 
The method used to determine the relative 
proportion of young women in the study from 1974 to 
1983, and also in the ensuing time period 1984 to 1988, 
was a geographically based one, thus making the 
measured proportions generalizable by correcting for 
referral bias. For the study period, the exact number 
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of young women and their domiciles as well as the total 
number of women was known. Also known was the exact 
percentage of sampled older women not eligible because 
of a domicile outside the Cape Town natural 
geographical area. From this the total number of older 
women living in the correct area could be estimated and 
the relative proportion of young women could then be 
calculated. 
A comparison of computer-generated data with data 
from the manual study shows that programming became 
reliable for carcinoma of the cervix by 1982. In this 
way all young patients could be traced from a 1984-1988 
patient list (excluding stage IA). The total patient 
number could also be determined for this time period. 
A sample of older women was obtained using the next 
highest numbers system and, · finally, all the domiciles 
were checked manually using the summary control sheets 
(Figure 1). 
2.3 EXCLUSIONS AND LOSSES 
Exclusion criteria were applied uniformly to all cases 
prior to entry into the study. All young women were 
examined and 91 were excluded and 82 accepted. Random 
sampling ( as described in Section 2. 2) was then per-
formed on the older group. If an exclusion was made, 
it was recorded and the next highest number was pro-
ceeded to. In this way 93 older women were excluded by 
the time the random sample of 82 was obtained. A total 
of 1 522 cases of invasive carcinoma of the cervix were 
registered by the CAC over the period 1974 to 1983 in-
elusive. Of these, 173 were in the young group and 1 
349 in the older group. A total of 82 out of 173 
(47,4%) young women were eligible. In the older group, 
82 out of 175 {82+93) were eligible, i.e. 46,9%. This 
translates to 633 patients (i.e. 46,9% of 1 349). Thus 
the sample size of 82 out of 633 amounts to 13%. 
TABLE 1. STUDY EXCLUSIONS. 
YOUNG OLDER 
1 Domicile not in correct area 46 48 
2 No Groote Schuur biopsy 25 22 
3 Post-surgical (unstaged) 7 6 
4 Double primary malignancy 1 10 
5 Stump carcinoma 0 1 
6 Partly treated elsewhere ( 1 0 ) 0 1 
7 Recurrent carcinoma from elsewhere 1 0 
8 Referred from Tygerberg Hospital 1 1 
9 Patient refuses treatment 9 3 
10 Untreatable 1 1 
11 Vault recurrence (after CIN) 0 0 
91 93 
43 
The exclusion criteria and the numbers excluded 
for each group are liste~ in Table Il. Some of the ex-
clusions in Table I require comment: 
1. Domiciles beyond Springbok, Beaufort West and 
George were excluded for reasons described in Sec-
tion 2.2. 
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2. During the 1970's histology from other insti-
tutions or private pathologists was not regularly 
reviewed 
Pathology. 
by Groote Schuur Gynaecological 
4. It seemed justified to exclude these cases even 
though there is a vastly different occurrence of 
double primaries (not necessarily synchronous) in 
the young and older groups. It is impossible in 
these cases to judge the true influence of 
cervical carcinoma on patient survival. Any bias 
thus resulting (from a possible artificial 
prolonging of survival in the older group) would 
tend to make any decreased survival in the young 
group slightly more obvious. 
9. More young patients refused treatment than older 
patients. These patients were excluded because 
the study applied to patients. who accepted the 
treatment recommendation for the disease. Any 
bias (from an artificial prolonging of survival in 
the young group) would tend to make any decreased 
survival in the young group slightly less obvious. 
10. The untreatable patients consisted of a patient 
with a single pel vie kidney and advanced disease 
and another patient with a permanent sigmoid 




















Figure 5. Study Numbers 
• 
A total of 164 patients ( 82 + 82) were entered 
into the study. Of these, 6 were lost for technical 
reasons, comprised of 3 losses in each group and leav-
ing 79 patients in each group. The loss amounted to 
6\164 or 3,7% of the study. Not a single patient was 
lost due to lack of information, i.e. all patient 
records were obtainable. It was possible to obtain 160 
satisfactory archival slides out of 164 of the cervical 
biopsies and .other specimens from 1974 to 1983. A to-
tal of 2 patients were felt on review of the histology 
not to have cervical carcinomas, i.e. they had been 
misdiagnosed in the past. The 6 losses are further de-
tailed in Table II. 
















Yolk sac tumour. Probably secondary 
spread to the cervix. Palliative 
radiotherapy. stage 4. 
Archival material untraceable at the 
GSH Laboratory. 
Radiotherapy. Stage lB. 
Archival material untraceable at 
the GSH Laboratory. Stage 2B. 
Archival material untraceable at the 
GSH Laboratory. Stage 2B. 
Serous carcinoma with probable 









The overall study numbers are illustrated in Figure 5. 
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3.1 MISCELLANEOUS PATIENT CHARACTERISTICS 
3.1.1 Age 
The mean age of patients in the young group was 29,9 
years. There were no patients in the under 20 group, 
27 patients in the 20-29 group and 52 patients in the 
30-34 group. This "doubling up" distribution matches 
that seen in the literature. 59 , 60 The two youngest 
patients were 22 years old (Patient Nos. 43 and 149). 
The first patient had a Stage 3 Grade 2 squamous 
carcinoma and she died after 8 months with extensive 
distant metastases; the second patient had a Stage 
2B Grade 2 squamous carcinoma and she was lost to 
follow-up at 27 months while disease free. 
The mean age of patients in the older group was 
53,4 years. The oldest patient (No. 78) was 85 years 
old. She had a Stage 3 squamous carcinoma. There 
were 32 patients in the 35-49 age group, ~2 patients 
in the 50-75 group and 5 patients older than 75 
years. The 42 patients in the 50-75 year group were 
listed for possible use as a "classical cancer of the 
cervix reference set" for comparison with the under 
35 group in terms of survival. 
3.1.2 Race 
By far the majority of the patients were of the 
Coloured race group. This group amounted to 76% of 
47 
the patients in the older age group and 82% of the 
patients in the young age group. The proportion of 
Europeans was respectively 13% and 11% in the two age 
groups and of Blacks it was 11% of the older and 6% 
of the young. There was no statistically significant 
difference in racial distribution between the young 
and the older patients (Chi-squar~ 1,395 and p = 
0,498). See Table III. 




ROW % <35 2".: 35 
COL % (n=79) (n=79) TOTAL 
WHITE 9 10 19 
5.70 6.33 12.03 
47.37 52.63 
11. 39 12.66 
COLOURED 65 60 125 
41.14 37.97 79.11 
52.00 48.00 
82.28 75.95 
BLACK 5 9 14 
3.16 5.70 8.86 
35.71 64.29 
6.33 11. 39 
TOTAL 79 I 79 158 
50.00 50.00 100.00 
~ 




























































Z <O-- :':t.l' -:t: - • , • - • < - < ~-=- ... -.,, 
~ ;': 
J 
-· . . ...-:--~,-~ 

























f " ' .. ' . ,. 
' . :~: 


















































An analysis of parity gives the following result: 
total births in the young group 262; total births in 
the older group 424. Mean parity in the young group 
3,32. Mean parity in the older group 5,37. In the 
literature the mean parity in cervical carcinoma is 
between 3 and 4 (for all age groups combined).58 
3.1.4 Pregnancy 
48 
Patients pregnant at diagnosis (including patients up 
to 6 months post-delivery) amounted to 12, of which 
11 were in the young group {92%). The case numbers 
of these patients are as follows: 15, 21, 41, 61, 
63, 77, 85, 93, 105, 107, 151. Of the total number 
of young patients (i.e. 79), 13, 9% were pregnant. 
This compares with the 17% found by Stanhope et al in 
265 young women.77 
3.2 OVERALL SURVIVAL 
A computer generated survival curve based on informa-
tion from the data record sheet ( Figure 2; Questiqns 
18, 15) is shown in Figure 6. This illustrates the 
overall survival data for the young group versus the 
older group based on date of entry and date of 
termination due to death from disease, death from 
unrelated causes, loss to follow-up or alive at end of 
study as described by Kaplan and Meier in 1958 and 
further described by Peto et a1.1o 4 ,1o5 Also displayed 
are the confidence intervals for the data.107 It can 
49 
be seen that the upper 90% confidence interval for the 
older group is approximately on the survival curve for 
the young group. The young group has a better survival 
throughout by 10 to 12%; at 5 years it is 57% in the 
young and 46% in the older group. It can be seen that 
for both groups survival stabilizes markedly by 3 years 
and from between 6 and 9 years onwards there are few 
deaths. 
The events at the termination of the study were 
distributed as shown in Table IV. As can be seen, fol-
low-up was achieved in almost 80% of the patients. The 
quality of this follow-up varied but from Question 19 
of the data record sheet, selection of numbers 1 and 2 
show that 50 out of the 79 young patients (63%) and 57 
out of the 79 older patients (72%) had completely ade-
quate follow-up. This difference is not statistically 
significant (x 2 = 1.0423; p = 0,3073). 
TABLE IV. EVENTS AT TERMINATION OF THE STUDY. (N = 79) 
ALIVE DIED LOST TOTAL 
Ca. ex. Other 
<35 24 (30%) 35 (44%) 2 (3%) 18 (23%) 79(100%) 
~35 19 (24%) 42 (53%) 2 (3%) 16 (20%) 79(100%) 
Statistical analysis of the two survival curves in 
Figure 6 using the Mantel Haenszel ( or Logrank) test 
gives a chi-square value of 1, 6583 and a p-value of 
0,1978 104 . There is thus no significant difference in 
survival between the two age groups. In the young 
group the proportion surviving at 5 years is 0,584 and 
the proportion surviving at 3 years is 0,569. In the 
older group the proportion surviving at 3 years is 
0,455 and the proportion surviving at 5 years is 0,455. 
At 5 years the observed difference is o, 569-0, 455 or 
0,114 (11,4%). The power of the logrank test for the 
observed proportions at 5 years is 0,2912 or 29%. (At 
3 years the power is 36%)108. 
3.3 PROGNOSTIC FACTORS 
50 
As there is little doubt in the literature that stage 
is the most powerful of the prognostic factors, 7 the 
stage distribution of the two groups was tabulated 
(Table V) to see if an explanation could be found for 
the overall survival results of Figure 6. 
TABLE V. STAGE DISTRIBUTION (N = 79) 
STAGE ~35 YRS >35 YRS TOTAL 
(N = 79) (N = 79) 
* lB 34 (43% 12 (15%) 46 
2A 4 ( 5%) 5 ( 6%) 9 
2B 12 (15%) 11 (14%) 23 
3 24 (30%) 41 (52%) 65 
4A 4 ( 5%) 5 ( 6%) 9 
4B 1 ( 1%) 5 ( 6%) 6 
*Chi-square= 14,994; p = 0,01 for Stage lB 
51 
It can be seen that there is more early stage dis-
ease in the young group. Some of the stage groups are 
very small with 5 or less members. It was therefore 
decided to combine the stages to give a distribution 
for early stage disease and late stage disease - a con-
cept with well accepted clinical validity. 27 , 84 Early 
stage disease is taken as lB and 2A an~ late stage dis-
ease as all the rest. Early stage disease indicates 
operability and late stage disease to a greater extent 
signifies sytemic disease. 
illustrated in Table VI. 
This distribution is 
TABLE VI. DISTRIBUTION OF EARLY AND LATE DISEASE 
FREQUENCY 
PERCENT 
ROW % GROUP 
COL ~ 0 
<35 yrs ~35 yrs TOTAL 
1 & 2A 38 17 55 
24.05 10.76 34.81 
48.10 21. 52 
2B - 4B 41 62 103 
25.95 39.24 65.19 
51.90 78.48 
TOTAL 79 79 158 
50.00 50.00 100.00 
It can be seen that about half (48%) of the young 
group have early stage disease compared to 22% in the 
older group (Chi-square 12,300; p = 0,001, 95% inter-
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Survival comparison for 
early stage disease. 
Fig. 9: 
Survival comparison for 
late stage disease. 
•• 
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To remove the confounding effect of stage from the 
survival estimations of the two age groups, survival 
curves were computer generated for Stage lB in the 
young versus Stage lB in the older group ( Figure 7) , 
early stage disease (1B+2A) in the young group versus 
early stage disease in the older group (Figure 8) and 
late stage disease ( 2B-4B) in the young group versus 
late stage disease in the older group (Figure 9). As 
mentioned before, the broader stage grouping into early 
and late is to increase numbers in the group and en-
hance the statistical power of the comparisons. 
In all three illustrated survival estimates, time 
is given in years. Curve A is for the older group and 
curve B marks the young group. The points A or B rep-
resent the product limit survival estimates generated 
by the data ( see Section 3 .1 for the principle in-
· vol ved) 105. The asterisks mark points where the curves · 
cross each other. The curves do not cover the full 15 
years because of limitations by the censored data.105 
The next prognostic factor considered was tumour 
size ( Question 7 of Figure 2). In the young group 8 
tumours were of unclear size and in the older group 7 
were unclear in size, while in the young group 17 tu-
mours were less than 3 cm diameter compared to 8 in the 
older group. When this difference was corrected for 
stage it was found that all 17 small tumours in the 
young group and all 8 small tumours in the older group 
were in early stage disease. If one considers that 
there are 38 early stage tumours in the young group and 
17 in the older group {Table VI) there is clearly no 
significant difference in the distribution of tumour 
size between the two groups. 
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There were a total of 25 clinically endocervical 
tumours, 1 7 in the young group and 8 in the older 
group. Of these, 9 occurred in early stage disease in 
the young versus 3 in the older group. Two stage-
stratified contingency tables are presented for this 
data {Table VII). 
TABLE VII. ENDOCERVICAL TUMOUR DISTRIBUTION BY AGE. 
<35 YRS ~35 YRS TOTAL 
EARLY STAGE 17 38 55 
Endocervical 3 (·18%) 9 {24%) 12 
Not endocervical 14 29 43 
LATE STAGE 62 41 103 
Endocervical 5 (8%) 8 (20%) 13 
Not endocervical 57 33 90 
TOTAL 62 41 103 
Fisher's Exact Test: p = 0,0806 
Of these 25 tumours 7 were non-squamous (4 in the young 
I 
group (24%) and 3 in the older group {38%). 
Tumour grade was the next prognostic ~actor to be ana-
lysed (Question 23, Figure 2). It was noted that 20 
patients were inadvertently not graded during the his-
54 
tological review and therefore they were not included 
for analysis. Of these, 9 patients were in the young 
group and 11 in the older group. These were all 
squamous tumours. The remaining . squamous tumours in 
the study (125) were comprised of 62 in the young group 
and 63 in the older group (note that these figures are 
derived after removal of the non-squamous tumours - see 
next paragraph) . It was felt that Grade III tumours 
might carry a worse prognosis and a distribution for 
these tumours was obtained for the two groups. The 
result are shows 22 Grade III tumours out of 62 (35%) 
in the young group versus 17 Grade III tumours out of 
63 ( 27%) in the older group - clearly there is no 
significant excess of high grade tumours in the younger 
age group (Chi-square= 0,6929; p = 0,4051). 
There were 13 non-sguamous tumours out of 158; 8 
in the young group (10%) and 5 in the older group (6%). 
These tumours can be tabulated as follows: (Table 
VIII) . 
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TABLE VIII. NON-SQUAMOUS TUMOURS 
STUDY STUDY 
NO. <35 YRS NO. ~35 YRS 
45 Adenocarcinoma 10 Adenocarcinoma 






83 Adenosquamous 110 Adenosquamous 
119 Adenosquamous 126 Adenosquamous 
It is of interest to note that in the entire study 
of 158 patients a mucin stain was only used 9 times 
( 6%) ( 4 times in the young group and 5 times in the 
. older group). Three of these 9 proved mucin positive 
(1 in the young group and 2 in the older group). Also 
of interest is the fact that 4 of the 8 ( 50%) non-
squamous tumours were endocervical in the young group 
and 3 out of 5 (60%) in the older group. If one con-
siders only adenocarcinomas the figures rise to 67% and 
100% respectively. 
To determine if the excess of adenocarcinomas in 
the young group represents a significant difference, a 
contingency table was drawn up (Table IX) and Fisher's 
Exact Test performed. 
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TABLE IX. ADENOCARCINOMA BY AGE GROUP. 
YOUNG OLDER 
<35 YRS ~35 YRS TOTAL 
Adenocarcinoma 6 (8%) 2 (3%) 8 
Not adenocarcinoma 73 77 150 
TOTAL 79 79 158 
Fisher's Exact Test: p = 0,1381 
Lymph node involvement by cervical carcinoma was the 
next prognostic factor examined (Question 9, Figure 2). 
Analysis was made difficult by the stage skewing in the 
two groups. Far more lymph node sampling was done in 
the young group, i.e. 33 versus 7. In the young group 
7 out of the 33 samples proved positive (21%) and in 
the older group 2 out of the 7 (29%). The young group 
comprised 30 Stage lB' s and 3 Stage 2A' s. Of the 
latter, 1 patient had positive nodes. Thus, for Stage 
lB in the young age group, 6 out of 30 sampled patients 
had positive lymph nodes (20%). All the sampled 




TABLE X. STAGE IB POSITIVE NODES BY AGE GROUP 
SAMPLED STAGE IB YOUNG OLDER 
<35 YRS ~35 YRS TOTAL 
Nodes Positive 6 (20%) 2 (29%) 8 
Nodes Negative 24 5 29 
TOTAL 30 7 37 
Fisher's Exact Test: p = 0,4793 
Tumour recurrence data (Questions 11, 12, 13, 14; Fig-
ure 2) showed, firstly, that complete tumour regression 
was not achieved in all patients by the completion of 
treatment . In the young group there were - 14 ( 18%) 
residual tumours and in the older group 20 (25%) 
residual tumours. All these occurred in late stage 
disease. As the proportion of late stage disease in 
the old versus the young is 3 to 2 (i.e. 62 cases v. 41 
cases, see Table VI) there is no significnt difference 
in residual disease between the two groups. The number 
of tumour recurrences recorded for the young group is 
20 and for the older group 18, while the mean time to 
recurrence is 22 months in the young and 23 months in 
the older group. This latter data is dependent on 
follow-up information. Table IV shows that 61 (77.2%) 
in the young group and 63 ( 79. 7%) in the older group 
had follow-up information. Recurrence data (Question 
11 of Figure 2) were not entered except for these 
cases. This gives 20 out of 61 in the young group and 
18 out of 63 in the older group having disease 
recurrence, i.e. 33% versus 29%. This difference is 
not significant. It is possible that recurrence data 
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in the older group is under-represented because of old 
patients in the lost group who conceivably "give up" 
when the disease recurs and do not return for follow-
up. In general, survival in patients who develop 
recurrent disease ranges from 3,5 to 11% and recurrence 
is equivalent to death from disease.23 
. In the young patients there were 11 peripheral re-
currences (i.e. distant metastases) out of 20 ( 55%) 
compared to 6 out of 18 (33%) in the older group. Of 
these, 4 occurred in early stage disease in the young 
group and 2 in early stage disease in the older group. 
The distribution of distant· metastases (non-contiguous 
recurrent disease or both; see Question 12) between 
the age groups is given in Table XI. The actual sites 
of metastases are shown in Table XII. 
TABLE XI. DISTANT METASTASES BY AGE GROUP 
RECURRENCE YOUNG OLDER 
<35 YRS 2':35 YRS TOTAL 
Distant 11 (55%) 6 (33%) 14 
Contiguous 9 12 21 
TOTAL 20 18 38 
Chi-square= 1,0292; p = 0,3103 
TABLE XII. SITE OF DISTANT METASTASES. 
NO. YOUNG GROUP NO. OLDER GROUP 
7 VT node 6 VT node 
9 VT node 16 Hepatic 
13 VT node + hepatic 32 Hepatic + pulmonary 
29 VT node + brain 92 Brain+ pulmonary 
33 VT node + pericardium 108 Brain+ pulmonary 
43 Hepatic 150 Bone 
59 Malignant ascites 
65 Brain+ pulmonary 
105 Pericardium 
127 Pulmonary, breast, · 
bone 
157 Pulmonary+ bone 
The histological type of the recurrent tumour cor-
responded with that of the primary tumour in all the 5 
biopsies that were done in the older group and in 10 of 
the 11 biopsies in the young group. Individual 
inspection of the non-corresponding case (29) shows it 
to be from a 33 year-old patient with a Stage 3 
squamous carcinoma as the primary tumour. The tumour 
The tumour was Grade 2. A mucin stain was not used. 
recurred 28 months later as widespread distant 
metastases (pulmonary, breast, bone). Biopsy at that 
stage revealed a poorly differentiated adenocarcinoma. 
She died 11 months later. 
Of the 20 recurrences in the young group, 7 
occurred in early stage disease ( 35%) and of the 18 
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recurrences in the older group 4 occurred in early 
stage disease (29%). 
Of the 38 recurrent tumours in the overall study, 
16 were biopsied - 11 in the young group (55%) and 5 in 
the older group (28%). (See Questions 13 and 22, Figure 
2). This distribution is shown in Table XIII. 
TABLE XIII. BIOPSY OF RECURRENCE BY AGE GROUP 
RECURRENCE YOUNG GROUP OLDER GROUP TOTAL 
Biopsied 11 (55%) 5 (28%) 16 
Not biopsied 9 13 22 
TOTAL 20 18 38 
Fisher's Exact Test: p = 0,5275 
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The results of the evaluation of the length of the 
preinvasive phase in the two age groups as detected by 
cytology are now presented (Question 32; Figure 2). Of 
the 158 patients only 14 had results of negative 
cytology performed in the preceding 5 years. Of these, 
8 were in the young group and 6 in the older group. 
The mean time from negative cytology to diagnosis of 
carcinoma was 20 months in the young group (range 7-36 
months) and 24 months in the older group (range 4-53 
months). In a total of 4 patients in the young group 
this preinvasive phase was 12 months or less, while in 
the older group 3 patients fell into this category. 
Of the remaining 144 patients, 7 (3 young, 4 
older) had partially incomplete screening results (See 
Question 3, Figure 2) and 137 had no cytology result 
available prior to diagnosis (i.e. 87%). A total of 95 
patients had cytology results available at diagnosis 
(Question 29) (51 young, 44 older). Of these, 75 
61 
(78,9%) gave the diagnosis of an invasive lesion. In 
the young group there were 37 and in the older group 
38; with co:i:-responding false negative results of 14 
(27%) and 6 (14%). Only 4 in the young group and 1 in 
the older group were totally negative (i.e. not even a 
preinvasive lesion detected), giving truly false nega-
tive rates of 8% in the young and 2% in the older 
group. See Table XIV. 
TABLE XIV. TRULY FALSE-NEGATIVE CYTOLOGY DISTRIBUTION 
YOUNG GROUP OLD GROUP TOTAL 
FALSE NEGATIVE 4 1 5 
TRUE POSITIVE 47 43 90 
TOTAL 51 44 95 
Fisher's Exact Test: p = 0,2303 
3.4 TREATMENT TYPE AND COMPLICATIONS 
The mode of primary treatment (Question 8, Figure 2) is 
highly dependent on both disease stage and patient age. 
overall, 103 patients received radical radiotherapy as 
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the primary mode of attempted cure and 30 patients 
received only radical surgery. It should be noted 
(from Section 3.3 on lymph node sampling) that a total 
of 40 patients were initially subjected to a surgical 
attempt at cure. In only 31 cases (78%) was a curative 
procedure possible. In 14 patients in the study, 
palliative treatment only was given and in 11 cases no 
treatment was recommended . . A breakdown of the primary 
treatments according to disease stage (i.e. early stage 
or late stage) and patient age ( young or older) is 
given in Table XV. 
TABLE XV. TREATMENT ACCORDING TO AGE AND STAGE 
YOUNG GROUP (<35) OLDER GROUP (~35) TOTAL 
Stage Stage ' 
Early Late Early Late 
RR 13 (16%) 34 (43%) 12 (15%) 44 (57%) 103 
RS 25 (32%) 0 (0%) 
PR 0 (0%) 4 (5%) 
PS 0 (0%) 1 (1%) 
NT 0 (0%) 2 (3%) 
38 41 
RR= Radical Radiotherapy; 
PR= Palliative Radiotherapy; 





(6%) 0 (0%) 30 
(0%) 8 (10%) 12 
(0%) 1 (1%) 2 
(0%) 9 (11%) 11 
17 62 158 
RS= Radical Surgery 
PS= Palliative Surgery 
There appear to be clear differences in the young 
arid older group with regard to use of radical surgery 
in early stage disease (32% versus 6%). Reference to 
Table VI shows that there are 38 early stage cases in 
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the young group versus 17 in the older group. A con-
tingency table shows the following distribution (Table 
XVI). 
TABLE XVI. RADICAL SURGERY BY AGE GROUP 
YOUNG GROUP OLDER GROUP TOTAL 
SURGERY 25 5 30 
NO SURGERY 13 12 25 
TOTAL 38 17 55 
Chi-square= 4,8877; p = 0,0270 
It can also be noted from Table XV that more of 
the older patients were not offered any primary 
treatment (9 patients v. 2 patients), probably in 
keeping with the more advanced nature of the disease in 
this group (see Table V). Of the older group 51 .had 
Stage 3 or 4 disease compared to 29 in the young group; 
more importantly, 10 had stage 4 compared to 5 in the 
young group. 
Treatment of recurrent disease (Question 14, 
Figure 2) was assessed to see if there was any 
difference in intensity of secondary treatment in young 
versus older patients. Reference to Table XI shows 20 
recurrences in the young group versus 18 in the older 
group. The distribution of treatment is shown in Table 
XVII. No patient in the study had pelvic exenteration 
performed. Chemotherapy was not systematically or 
extensively used during the study period ( 1974-1983) 
but was sometimes combined with other secondary 
treatment modalities; recorded here are those cases 
where it was used alone. (Table XVII). 
TABLE XVII. TREATMENT OF RECURRENT DISEASE 
INITIAL STAGE 
SECONDARY 
Young Groug Older Groug 
TREATMENT Early Late Early Late 
Nil 2 7 2 9 
Full dose irradiation 4 2 1 2 
Palliative surgery 1 0 0 0 
Chemotherapy only 0 2 0 1 
Reduced dose irrad. 0 2 1 2 
TOTAL 7 13 4 14 
64 
Examination of the table does not show any appar-
ent bias towards younger women except in full-dose 
irradiation for recurrent early stage disease - which , 
would be expected because of the increase use of 
surgery as primary treatment in this group. 
Returning to primary therapy, the relative major 
complication rates of the various treatment modalities 
were assessed after one year (see Question 10, Figure 
2) • 
In the young group, 26 ( 51%) patients out of 51 
treated had no treatment complications worth mentioning 
after one year compared to 23 (49%) out of 47 treated 
patients in the older group. (In both groups patients 
with residual . disease or recurrent disease before 1 
year were excluded as were those lost to follow-up) . 
In the remaining pati'ents there were 9 major com-
plications requiring surgery, 5 in the young group and 
4 in the older group (See Table XVIII). 






(n = 51) 
Laparotomy for 
chronic lymphocyst 
Hot flushes x3 
Bladder symptoms x2 
Chronic wound sinus xl 
Nephrectomy 
Urinary diversion 
Death (rectal n~crosis) 
Hot flushes x2 
Bladder symptoms xl 
Vaginal stenosis x7 








Death (sepsis from 
bowel obstruction) 









It can be seen that there were two deaths, one 
from each group, both resulting from radiotherapy. If 
one compares the complications of surgery versus radio-
therapy in the young group where 32% had radical 
surgery (see Table XV), it appears that radiotherapy 
gives more serious complications. Note that the com-
plications which are recorded are the ones that caused 
real problems for the patient and dominated the follow-
up visits. 
selected. 
The single most troublesome complaint was 
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If one compares the radiotherapy complications in the two 
groups, there are few differences. What is of note in the 
young group is the large vaginal morbidity of radiotherapy. 
3.5 EVIDENCE OF HUMAN PAPILLOMAVIRUS INFECTION 
The histology slides of all 158 patients in the study 
were examined for histological evidence of HPV infec-
tion (see Section 1.2). This information was not re-
ported before in the original filed reports. Analysis 
of Questions 26 and 27 (Figure 2) gives the following 
results: 
There were 18 cases positive for HPV in the young 
group and 7 positive in the older group. However, 
there were also more evaluable cases (i.e. cases with 
non-neoplastic epithelium present on the slide) in the 
young group, i.e. 46 versus 25. To determine if a sig-
nificant difference was present in the distribution of 
HPV between the young and the older group in the 71 
evaluable cases, a contingency table was drawn up 
(Table XIX). Evidence of HPV was found in one case of 
adenocarcinoma and in a case of adenosquamous carcinoma 
- both in the young group. The overall HPV pickup rate 
for all the 71 evaluable cases was 25 (or 35%). In the 
entire study of 158 cases of cervical carcinoma, 25 
cases (16%) could be found to have HPV present. 
TABLE XIX. DISTRIBUTION OF EVALUABLE HPV 
YOUNG GROUP OLDER GROUP TOTAL 
<35 YRS ;:::35 YRS 
HPV Present 18 (39%) 7- (28%) 25 
HPV Not Present 28 18 46 
TOTAL 46 25 71 
Chi-square = 0,4593; p = 0,4979 
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Examination of cytology data in Section 3.3 showed 
that only 7 patients had abnormal cytology results 
available prior to diagnosis and a further 90 had 
abnormal results available at diagnosis. (Note that 
the cytology laboratory stores only abnormal slides) . 
Thus there were potentially 97 slides available for 
review, an unknown proportion of the 97 reports being 
from outside cytologists. A total of 48 slides were 
ultimately obtained after a full search of the cytol-
ogy archival material, 1974-1983. (Unlike the histol-
o_gy section, lack of cytology done at Groote Schuur 
Hospital was not made an exclusion criterion for the 
study). There were 23 slides available in the young 
group and 25 slides available in the older group. A 
total of 10 slides (21%) were positive for HPV by cyto-
logical criteria, 6 in the young group and 4 in the 
older group. These results are displayed in Table XX. 
TABLE XX. HPV AT CYTOLOGY 
HPV Present 




6 ( 26%) 
17 
23 
Fisher Exact Test: p = 0,307 
OLDER GROUP 
?:35 YRS 








To determine the correlation between histology and 
cytology, the 10 HPV-positive cytology cases were 
cross-referenced with the histology result. The result 
is shown in Table XXI. 
TABLE XXI. CASES WITH POSITIVE CYTOLOGY VS. HISTOLOGY 
CASE CYTOLOGY CYTOLOGY HPV HISTOLOGY HPV 
WITH COMMENT 
46 Malignant +ve -ve Not evaluable 
47 Malignant +ve +ve Evaluable 
51 Malignant +ve +ve Evaluable 
61 Malignant +ve -ve Evaluable 
67 Malignant +ve -ve Evaluable 
78 Malignant +ve -ve Not evaluable 
111 Malignant +ve -ve Not evaluable 
144 Malignant +ve -ve Evaluable 
153 Malignant +ve -ve Evaluable 
154 Malignant +ve -ve Not evaluable 
Table XXI shows that 7 of the cases with HPV-
positive cytology could be checked against the 
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histology (i.e. adjacent non-neoplastic epithelium was 
present in 7 of the corresponding histology specimens). 
In these, the majority, i.e. 5 out of 7, were negative, 
demonstrating a lack of positive correlation between 
cytology and histology in the detection of HPV 
infection. 
3.6 THE PROPORTION OF YOUNG PATIENTS 
This was determined on a geographical basis, making use 
of the patient's usual home address as the inclusion or 
exclusion factor; otherwise all registered cases of 
invasive carcinoma of the cervix were included in the 
calculations (see Section 2.2). 
' The total number of young patients for 1974-1983 
was 173. Of these 46 did not live in the correct area 
and 127 did (73,42%). ( see Section 2. 3) . The total 
number of older patients was 1349~ Of these a sample 
of 175 was taken (of which 82 were ultimately eligible 
for the study and 93 were excluded). Of these, 48 did 
not live in the correct area and 125 did (71,43%). 
Applying the latter proportion to all the older cases 
gives 71,43% x 1349 = 964 older patients in the correct 
geographical area. 
The proportion of young women is given as 127 in 
964 + 127, i.e. 127 in 1091 or 11,6%. 
To see whether the proportion of young women 
changed during the subsequent 5-year period directly 
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following the study and included in its follow-up 
period, i.e. 1984 to 1988 inclusive, calculations were 
made as follows: a computer printout was obtained of 
all cases of invasive carcinoma of the cervix for this 
time period ( Comparison of computer data with manual 
data over the years 1981, 1982 and 1983 showed that the 
computer data was fully reliable in terms of 
registration data by 1982). This yielded a total of 
879 patients. Of these, 122 were less than 35 years of 
age and 757 equal to or older than 35 years of age. 
The patient's usual home address could not be obtained 
from the computer. A manual sample was therefore taken 
of the patient records and the data obtained from here 
(see Section 2.2) is as follows: (Table XXII). 
TABLE XXII. DISTRIBUTION OF USUAL DOMICILE 
DOMICILE YOUNG GROUP OLDER GROUP TOTAL 
Correct area 83 (68%) 101 (83%) 184 
Incorrect area 39 21 60 
TOTAL 122 122 244 
Chi-square= 6,3873; p = 0,0149 
In the 1984 to 1988 period, the correct (local) 
domicile in . the young was 68% ( compared to 73% for 
1974-1983), while the correct domicile in the older 
patients was 83% (compared to 71% for 1974-1983). 
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Applying these new proportions to the patient list 
of 1984 to 1988 yields 83% x 757 = 628 older patients 
from the correct geographical area. 
The proportion of young women is given as 83 in 
628 + 83, i.e. 83 in 711 or 11,7%! 
3.7 STATISTICS AND MULTIVARIATE ANALYSIS 
The statistical analyses have mostly been reported si-
multaneously with the results. The results have been 
mostly categorical data. 
The main body of these statistics involves the 
parameter of rate, known also as proportion. A rate is 
obtained for the young group of a certain event and a 
rate is obtained for the older group of a certain event 
and the two rates are then compared after being dis-
played in a contingency table. The statistical method 
of comparing rate is the chi-square test. 109 There are 
a number of modifications of this test to accommodate 
numbers smaller than 10 per cell, e.g. the Yates conti-
nuity correction for cell frequencies of 5 to 9 and the 
Fisher exact probability test for cell frequencies of 
less than 5. The alpha value has been taken as O, 05 
throughout and it has been used for a two-tailed phe-
nomenon. 
The survival curves have been , constructed and 
interpreted in the standard way described by Peto et 
a1. 104 The curves have been generated using the 
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standard method of nonparametric estimation from 
incomplete observations of Kaplan and Meier.105 
Statistical comparison of survival curves is by 
the standard logrank method (the Mantel-Haenszel 
testl04). These complex mathematical functions were 
conducted for this study by the Institute for 
Biostatistics of the Medical Research Council in Parow. 
All the numerical data for the graphs and statistics 
are in the possession of the investigator. The chi-
square computations were conducted on a personal 
computer by the investigator using the "Epistat" 
statistics program. 
Further analysis of the survival data for 
confounding variables is described further below but 
essentially it involved (a) stratifying the data for 
unconfounded logrank comparisons ( smaller studies 
within a study) ; ( b) a proportional hazards general 
linear model procedure.98 (Multivariate Analysis). 
As described in Section 3 .1, there is no 
significant difference in survival between the young 
and the older groups even when compared stage for 
stage. There is the possibility that other confounding 
f.actors are obscuring a significant difference, e.g. 
type of treatment or type of tumour. 
A survival curve was generated for treatment type 
and displayed according to early stage of .late stage 
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Fig. 10: 
Survival comparison for 
treatment type by stage . 
Fig. 11: 
Overall survival estimates 
for radiotherapy in 
squamous carcinoma . 
Fig. 12: 
Overall early stage 
versus late stage 
survival. 
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( Figure 10) . Ref er to Section 3. 4, Table XV for the 
relevant numbers. 
To remove the possible confounding effect of 
tumour type on survival, a homogeneous treatment 
modality was selected 
largest patient numbers) 
(squamous carcinoma to 
(Radiotherapy, to give the 
for a specific tumour type 
give the largest patient 
numbers) and survival was then compared in the two age 
groups. See Figure 11) . Using this data and also 
previous stage distribution data (see Section 3.3.) for 
covariate correction of the Mantel-Haenszel test a chi-
square of 1,9312 and a p-value of 0,1646 were obtained. 
This gave the best evidence so far in the study that a 
difference might be present, but it was not 
significant. 
To graphically illustrate the effect of stage, the 
study patients were divided into early stage disease (n 
= 55) and late stage disease (n = 103), irrespective of 
age group. The survival graphs are illustrated in Fig-
ure 12. The difference in survival is highly signifi-
cant: chi-square - 28,703842 and p = 0,0001. 
Using all the illustrated covariate information 
geDerated so far by stratifying the information in the 
Mantel-Haenszel equations, the following results can be 
tabulated (Table XXIII): 
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TABLE XXIII. SIGNIFICANCE OF PROGNOSTIC VARIABLES 
VARIABLE CHI-SQUARE p-VALUE 
Disease stage 28,7038 0,0001 
Age group 1,9312 0,1646 
Treatment type 2,3900 0,1221 
Tumour type 2,4405 0,1182 
All the previous statistical work has, by 
univariate stratifications, diminished the power of the 
study to detect a real difference (by effectively 
reducing comparison numbers). The univariate analysis 
is not able to test the simultaneous effect of all the 
covariables on all the data. This effect can be 
achieved by multivariate analysis, 98 which, in dealing 
with survival data, makes use of the proportional 
hazards method best described by Cox. By using this 
method the confounding effect of the disease stage 
difference between the two comparison groups (young and 
older) is effectively removed and the only factor 
affecting study power now becomes study number. The 
full effect of the large study number of 79 + 79 can be 
used. 
A multivariate analysis was performed on the data by 
the Medical Research Council Institute for Biostatis-
tics based on the general formula: 
where 
A(t: z) is the hazard function (i.e. 
instantaneous rate of failure at T = ;t.), z denotes 
the covariates, B the regression parameter, and 
AO ( ~ ) an arbitrary baseline hazard function. 
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The result of the multivariate ·analysis shows 
that, as in the logrank analysis earlier, the age 
effect is non-significant (p = 0,8498). The estimated 
95% confidence interval for Bis -0,502 <B<0,414. This 
interval includes O and supports the hypothesis-test 
result (i.e. p-value). The obtained value for B 
(excluding · the given confidence intervals is 
0,04430092. This indicates that the older age group 
has a decreased hazard function (being a negative 
sign), although this finding is not significant. In 
other words, the older age group has a non-significant, 
relatively decreased hazard of death. 
discussed further in Section 4. 
This is 
The key statistical findings of the multivariate 
analysis are displayed in Table XXIV. 
TABLE XXIV. MULTIVARIATE ANALYSIS OF AGE GROUP AND 











The study was motivated by the conflicting evidence in 
the literature on the nature and prognosis of cervical 
carcinoma in young women. A number of reports have con-
cluded that there are important differences in disease 
characteristics and/or survival in young women compared 
to their older counterparts.24,40,42,61,64,69,70-79,80,96 
Conversely, t,here is a considerable body of 
evidence that no such differences 
women.27,37,39,48,59,63,81-95 
exist in young 
The personal feeling of those working closely with 
the disease prior to the study was that there may well be 
important differences in the disease in young women and 
in particular that their survival might be worse, 
especially in early stage disease. The study had the 
added motivation of resolving the issue in a local 
context where patient populations differ from those 
reported in the literature. 
List of Findings 
The study generated a large number of findings. For ease 
of reference they are given below in list form. 
There is no significant overall difference in 
survival between young and older women, they have a 
similar follow-up attendance, there is a significantly 
different stage distribution between the groups, t~ere is 
no significant difference in tumour size for stage or 
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endocervical tumour site between the two groups or any 
significant excess of high grade tumours or 
adenocarcinoma or non-squamous tumours in general in the 
young group, as well as no significant difference in 
metastasis to lymph nodes. There is no difference in 
residual disease following correction for stage, no 
significant difference in rate of recurrence or mean time 
to recurrence, no predilection for early stage recurrence 
in the young and no significant difference in rate of 
distant metastasis or site of metastasis. Recurrences 
are treated with a similar intensity in the two groups 
and there is no significant difference in the number of 
recurrences biopsied. There is no evidence of a 
significantly shorter preinvasive phase of the disease in 
young patients or a higher false negative cytology rate. 
There is a significant difference in type of treat-
ment given in the two groups with surgery being more 
favoured in the young. There is no difference between 
the age groups in the overall number of patients with 
treatment complications. 
Compared to radiotherapy, the complications of 
surgery seem less severe in the young. Vaginal stenosis 
occurs with similar frequency in both groups following 
irradiation. Evidence of Human papillomavirus (HPV) is 
found in 35% of evaluable histology slides and in 21% of 
cytology slides of cervical carcinoma. There is no 
significant excess of HPV in the young group. There is a 
lack of positive correlation between histological and 
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cytological assessment of HPV. Invasive cervical 
carcinoma is fairly common in women between 20 and 35 
years of age. There is no recent increase in the local 
proportion of young patients with cervical carcinoma; 
however, a greater number of young patients are being 
specially ref erred to Groote Schuur Hospital. Analysis 
of survival in the two groups corrected for the confound-
ing variables of stage, tumour type and type of treatment 
shows no significant difference in survival rate, even 
after formal multivariate analysis. In the latter analy-
sis the older group shows a small, non-significant reduc-
tion in the hazard of death. 
Further notable findings are that the overall sur-
vival curves have a long term shape compatible with that 
found in the literature, while the age distribution in 
the young group is similarly compatible, as is their 
pregnancy rate. The race distribution in the two study 
groups is similar. A mucin stain was used in only 6% of 
cases, while in 1 out of 11 biopsied recurrences of squa-
mous carcinoma in young women a previously undiagnosed 
adenocarcinoma was found. The study patients have sparse 
previous cytology results. Tumour type and treatment 
type .do not significantly affect survival, while stage 
has a profound effect on survival. 
A summary of the positive findings of the study is 
as follows: There are 
tumours in the young group 
significantly 
(p = 0,01), 
more stage lB 
surgery is used 
significantly more often in young patients (p = 0,027) 
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and the difference in survival between disease stages is 
highly significant (p = 0,0001). 
STUDY ACHIEVEMENTS 
It can be seen from the study findings that the study 
objectives (Section 1.4) have largely been achieved. As 
most of the findings were of a negative or "no 
difference" nature, any further di vision of the study 
into smaller "studies-within-a-study" as originally en-
visaged in the study protocol, e.g. "comparison of the 
group under 35 with a classical group aged 50 to 75", 
etc., was resisted, and instead the analytical method of 
multivariate analysis was resorted to conserve the 
study's power to detect a real difference98 (thus achiev-
ing the stated objective of maximizing the chance of 
finding a real difference). For similar reasons some of 
the very extensive subcategorization in the data 
collection sheet was ultimately avoided in the data anal-
ysis. A few aspects of the data (i.e. Questions) were 
not used at all as it became clear during the practical 
collection of the data that the information sought was 
incomplete or non-objective. Thus, results are not pre-
sented for Question 16 (Direct cause of death) or Ques-
tion 25 (Angiolymphatic permeation status). In the for-
mer case this is seldom described in recorded information 
beyond vague terms and in any case death often ultimately 
occurred at home. In the latter case the assessment of 
angiolymphatic space (i.e. preformed space, or channel) 
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invasion could not be done on punch biopsy histological 
material and this precluded most of the study subjects. 
STUDY DESIGN 
The overall study design (Figure 5) follows a well 
recognized format. 98, 99,101 Of note is that a random 
sample is used for the older group. All sampling is sub-
ject to an inherent random sampling error, i.e. the mean 
of the sample will not fall exactly on the mean of the 
population; however, a greater than 10% sample, as in 
this study which used 13%, can generally be considered to 
be adequate.109 In the Materials and Methods section it 
may further be noted that various exclusion criteria were 
used (Table I), some of which have a skewed distribution 
between the two age groups. The effect of excluding the 
many older patients with a qecond malignancy, al though 
making for a more accurate estimation of survival in 
cervical carcinoma, will possibly tend to reduce the 
hazard of death in the older group thereby making any de-
creased survival in the young group more obvious. 
PATIENT SURVIVAL 
The major result of the study is the survival analysis, 
as this is the practical measure of any difference in 
cervical carcinoma in young versus older women. Any 
significant difference detected in survival would have 
major implications for screening programs, treatment pro-
tocols and aetiological analyses. It is not sufficient 
to display survival data as a mean value, e.g. "mean sur-
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vi val 37 months", as this is notoriously inaccurate .104 
The Life Table method, which is a graph or table giving 
an estimate of the proportion of a group of patients that 
will still be alive at different times after randomiza-
tion, calculated with due allowance for incomplete fol-
low-up, is the only generally accepted way to present and 
analyse such data.104 
This study fails to show a significant difference in 
survival between the two age groups. Comparing the two 
survival curves uncorrected for confounding variables 
gives a p-value of 0,198. As the observed difference be-
tween the groups is low (of the order of 10 to 12%), the 
power of the logrank test (at its maximum 3-year value) 
is only 36%. 108 Therefore, this study shows that for the 
actually observed data the 98% chance of being 80% sure 
of showing a significant difference is only 36% (at a= 
o;os and B = 0,20). on the other hand, as the pre-study 
power calculation ( see Section 1. 4 and 2. 2) showed, an 
80% chance of finding a real difference would have 
occurred if the difference in survival between the two 
groups had been observed to be in the region of 50%. 
This study might the ref ore be missing a real difference 
in survival if this difference should be less than 50%, 
even though the achieved result shows "no significant 
difference in survival". Alternatively, it is highly im-
probable, given the actual results of this study, that 
the difference in survival between young and older 
patients is greater than 50%. 
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Most of the studies in the literature support the 
conclusion that there is no worse survival in young 
versus older patients with cervical carci-
noma27,37,39,40,48,59,61,63,64,81-95. One of the most 
important of these studies, that by Meanwell et al, 1988. 
was done on 10 022 patients to determine the prognostic 
effect of age59. They divided patients into under 40 
years and greater than or equal to 40 and found 5-year 
survival for the young group to be 69% and for the older 
group to be 45%. The overall survival difference, unlike 
the present study, was found to be significant (logrank 
p-value <O, 0001) ; however multi variate analysis for 9 
covariables showed that age was, if anything, a small but 
favourable factor. Similarly, another modern study on 
2011 patients using adequate statistics including multi-
variate analysis with the Cox . proportional hazards model 
( Junor et al 1989) showed no significant difference in 
survival in young versus older patients. 61 All the 
patients in that study received identical radiotherapy. 
A study similar in design to the present one (Carmichael 
et al), in which 121 patients under 35 years of age were 
compared to a random sample of 242 older patients, showed 
a significant difference in overall survival which 
disappeared after correction for stage.95 
In the present study it was felt that further analy-
sis controlling for the confounding effect of covariables 
would possibly find a significant difference in survival 
not seen in the overall results. For example, a true de-
83 
crease in the survival of young patients might be ob-
scured by an excess of early stage young patients com-
pared to the older group, or possibly the young patients 
had better treatment. 
curves comparing survival in the young and older age 
groups stage for stage, by stratified logrank analysis 
(Figures 7-9) show p-values of 0,425 fo_r lB versus lB, 
O, 714 for Early Stage versus Early Stage and O, 714 for 
Late Stage versus 
for stage thus 
Late Stage. 
shows even 
Comparing survival stage 
less likelihood of a 
significant difference in survival than the overall 
comparison. Using the full numbers of the study, i.e. 79 
versus 79, a multi variate analysis controlling for the 
effect of stage shows that the effect of age on survival 
is non significant. The p-value here is only 0,850. The 
effects of treatment type and tumour type on survival are 
non-significant. The effect of stage is highly 
significant (p = 0,0001). 
Seeing that no significant difference in survival 
could be found between the two age groups in this study 
(and the power constraints have been discussed), the 
question arises of whether the two groups really are com-
parable or whether there is some as yet unmentioned bias 
masking a true difference in survival. One of the most 
common sources of bias in a case-control type comparison 
is the so-called prevalence-incidence or Neyman bias103 
by which is meant that the most acutely ill patients, who 
do not get into the proper management channels, may be 
84 
missed in an institutional study. In the specific in-
stance of cervical carcinoma, this bias would seem to 
play a minimal role as the disease is not usually acutely 
fatal and would almost always be referred into a regional 
centre for further management. Another common bias, the 
admission rate or Berkson bias103 , would not apply in 
this study as all patients in both groups would be regis-
tered (admitted). There is, however, the small possibil-
ity that some patients who had initial radical surgery 
might have escaped subse~uent registration by the CAC. 
If this were so, the observed survival of the young in 
the present study might be too pessimistic. 
Survival curves, to be truly accurate, need to be 
adjusted for population national mortality rates1° 4 . 
These rates are age-dependent and will affect survival 
curves for older patients more than for young patients. 
The survival curves used in this study could not be mor-
tality rate adjusted by the Medical Research Council as 
the race-specific national mortality rates are not accu-
rately known in South Africa. The nett result is that 
survival in the older group . will appear better than it is 
in reality. 
Analysis of 24 articles in the literature which 
support a conclusion of no worse survival in young 
patients shows the following breakdown of numbers studied 
in approximate increasing order of young patients for 
study. 
TOTAL PATIENTS 
27 Berkowitz et a188 
' 
28 Kahanpaa94 
210 Gusberg & Herman37 
218 Spanos et a18l 
305 Smales et a163 
107 Mann et a183 
59 Kyriakos et a194 
100 O'Brien & 
Carmichael 27 
762 Van Voorhis85 
185 Alvarez et a184 
820 Blomfield et a139 











103 Le Vecchia et a186 (<35) 
1125 Gilmour et a140 
121 Carmichael et a195 (<35) 
1418 Dodds & Latour82 
1451 Decker et a164 
168 Gerbaulet et a191 
























1964-1984 2011 Junor et a16l 
2870 Russel et a192 
10022 Meanwell et a159 
(Young do better) 1971-1978 
(Young do better) 1957-1981 
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Note that it is the number of young patients in a 
study that is important as it is their prognosis which is 
uncertain. The present study, which is based on 79 young 
women, is a middle ranking study in terms of the surveyed 
literature which shows no significant difference. 
OTHER NATURAL HISTORY CHARACTERISTICS 
. Turning now to other aspects of the present study, the 
numerous negative findings of comparisons between the 
young and older groups for differences in natural history 
characteristics deserve comment. Often these contingency 
table numbers relate to subgroups of the study and are 
much less than 79 on each side, e.g. Table X which has 30 
in one group and 7 in the other; with 6 events in the one 
and two in the other. 
ing a difference of 1 
To have an even chance of detect-
3. or more, one needs about 20 
ev~nts; while for a 2 3 difference one needs at least 
100 events .110 The various negative findings should be 
interpreted in this light. There is, nevertheless, ample 
support in the literature for all the findings of this 
study as listed at the start of the discussion. 
It has become increasingly clear that tumour size 
(or more correctly, tumour volume) may relate to the risk 
of lymph node metastasis and thus to prognosis; 22, 28, 23 
studies by O'Brien & Carmichae12 7 and Alvarez et a184 are 
in agreement with the findings of this study that young 
women do not have an excess of large tumours. There has 
been speculation that young women might have a greater 
proportion of high grade tumours. 69 Both Gilmour et a140 
87 
and Hall & Monaghan80 provide evidence for this and al-
though the present study found 35% high grade tumours in 
the young versus 27% in the older group, this could not 
be shown to be significant. Chang et al 26 on the other 
hand, in a major study of grade and prognosis, did not 
even consider an association between grade and age. 
There were 8 non-squamous tumours in the young group 
versus 5 in the older group. The study could not detect 
a significant difference; however, it is of interest 
that a full 10% of cervical carcinoma in the young group 
was not squamous. As a mucin stain was used in only 6% 
of the cases in the study, this proportion might be even 
higher, as Buckley et al 24 have pointed out. There is 
much evidence in the literature70,73 , summarized by 
Crowther and Shepherd, 33 that there has been an increase 
in the proportion of adenocarcinomas, particularly in the 
young. Adenocarcinoma might have a poorer prognosis than 
squamous carcinoma, 48 but there is also much evidence 
that this is not so.30,31 
There have been claims that spread to lymph nodes is 
more common in young patients. Elliott et al 73 , who 
studied 2628 women between 1953 and 1986 claimed that 
pelvic lymph nodes were being found positive more com-
monly in the young in the later yea rs of the study. La 
Vecchia et al 86, in a study of 103 young women, found 
lymph nodes positive in a very high 40% of. Stage lB (45 
cases). The present study found positive lymph nodes in 
20% of Stage lB in young women which is in keeping with 
classic teaching. 
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Al though the older group in the present study had 
more residual disease following primary therapy than the 
young group ( 25% versus 18%), the recurrence rate ( 29% 
versus 33%) and time to recurrence (23 months versus 22 
months) were very similar. Unlike Dattoli et al 74 and 
Mendenhall et al 72, who showed increased disease recur-
rence in young women, this study could not show a signif-
icant difference. 
Analysis of cytology factors in the two groups in 
the present study was hampered by the poor cytological 
screening histories of the study patients an under-
standable problem seeing that all the patients had devel-
oped a cervical carcinoma. Thus only 13% of the patients 
had any prior screening cytology results, which is in 
agreement with findings by Carmichael et a1 54 , who showed 
that 71,4% of 245 patients with cervical cancer in Canada 
had not been screened and Paterson et al 42 , who found 
similar results. Paterson also found a higher false neg-
ative cytology screening rate in young women who devel-
oped carcinoma. The present study found that the diagno-
sis of carcinoma was missed on cytology in a higher pro-
portion of young women than older women (27% versus 14%), 
but this could not be shown to be significant; simi-
larly, a significant difference in the length of the 
preinvasive phase could not be found. 
evidence that it may be shorter. 42 
Paterson provides 
Treatment is shown in the present study to vary ac-
cording to the age of the patient; thus significantly 
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more young women with early stage disease received radi-
cal surgery than older women with early stage disease (p-
value 0,027). This result is entirely expected as it has 
always been a general policy to prefer radical surgery in 
the patient who is younger and fitter; another reason to 
favour surgery in the young - is to preserve vaginal and 
ovarian function. Mann et a1 83 , in a series of Stage 1 
patients under the age of 40, found 81 had surgery versus 
26 with irradiation; this compared to 56 with surgery 
versus 43 with irradiation in an older group. The 
treatment of recurrent disease is shown in the present 
study to be of equivalent intensity, corrected for stage, 
in both age groups. 
Assessment of complications of treatment in the two 
age groups showed that an equal proportion of patients 
(±50%) had complications after one year following treat-
ment. The type of post-radiotherapy complication was 
very similar in both groups, where substantial numbers 
(59% in the young and 72% in the old) received this form 
of treatment in radical doses. The young patients, de-
spite their presumably greater sexual activity, had 
definite problems with vaginal stenosis post-radiother-
apy. Seibel et a1 50 in a study on sexual function after 
surgical and radiation therapy for cervical carcinoma 
found that patients in the irradiation group had signifi-
cantly less sexual enjoyment, controlled for age. An 
impression which is gained is that the late complications 
of surgery are less severe than those of radiotherapy. 
Mann et a183 had a similar finding that the complications 
of radiotherapy seem more serious than for surgery. In 
his study there were also two treatment related deaths, 
both following radiotherapy. 
Human papillomavirus infection can be found in 90% 
or more of cervical carcinomas by means of DNA hybridiza-
tion studieslO and this figure will probably approach 
100% with the advent of the polymerase chain reaction.14 
(See Section 1.2). Histology is not able to detect HPV 
infection in carcinoma cells but has a sensi ti vi ty as 
high as 80% in non-malignant epithelium. 21 In intraep-
i thelial neoplasia the detection rate is inversely pro-
portional to the severity of the lesion. 18 Cytology has 
a probable sensiti;ity for HPV of about 40% 20 , 21 in non-
malignant specimens and this declines when the disease is 
present, in a manner inversely related to severity. 10 In 
the present study, HPV was detected in 35% of the 
histologically evaluable cervical malignancies and in 21% 
of the malignant cytological material. The purpose of 
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examining the archival material in this way in the 
present study was to see if HPV was as prevalent in older 
women in 1974 - 1983 as it is today. The suspicion that 
there was a relatively lower prevalence in older women 
and thus a greater prevalence of HPV in the young group 
in previous times, indicating that HPV plays a new and 
undefined role in carcinoma of the cervix, could not be 
proven. The difference in HPV detected histologically in 
the young versus the old (39% versus 28%) had a ' p-value 
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of o, 498 and for cytology ( 26% versus 16%) the p-value 
was 0,307. 
PROPORTION OF YOUNG PATIENTS 
The study finding that there is no recent increase in the 
proportion of patients under the age of 35 years differs 
from many findings in Western countries. Smales et al 
in a United Kingdom hospital-based study, found the 
proportion of young women to increase from 2% to 18% in 
15 years 63 and Elliott et al, in an Australian hospital-
based study, saw an increase from 9% to 25% over 20 
years 73 . The British 10 022-case population-based study 
of Meanwell et al gave figures of 3,6% under 35 in 1960 
and 14, 5% under 35 in 198059 . The present study found 
the proportion of those under 35 to be constant at 11,6 
and 11, 7% ( in a hospital-based geographically corrected 
s~udy for 1974-1983 versus 1984-1988). An explanation of 
why the figures have not increased as in Meanwell et al 
might be that local patients did not experience the 
relative rise in sexual promiscuity seen in the West some 
2 O years ago. Alternatively, local patients are not 
having the diagnosis made at any earlier stage than 
before. Factors related to smoking in young people and 
to the use of the oral contraceptive may also be of 
importance4 , 5 
DISEASE STAGE 
One of the significant and surprise findings of the 
present study was the fact that more young patients have 
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early stage disease ( p = O, 01 for excess of Stage lB). 
Junor et al found 48% of patients under 45 years of age 
to have Stage 1 disease and they state that "We cannot 
explain the increased frequency of earlier presentation 
in younger women 11 6l. The finding that young women have 
earlier stage disease is widely confirmed in the 
literature. Carmichael et al in Canada found 64, 5% of 
women under 35 to have early stage disease versus 43, 0% 
(p <0,002) 95 . Similar results are reported by Russel et 
a1 92 , Spanos et a1 81 , Smales et a1 63 and Dodds and 
Latour82. The latter report is of interest because it is 
based on a patient series from 1926 to 1959, i.e. before 
cervical screening was widely current. Most of the 
studies mentioned above, including the latter, conclude 
that this discrepancy in stage distribution "may be 
partly explained by the tendency of younger women to seek 
screening procedures and by older women to disregard 
symptoms 1182 Although not stated in the literature, it 
seems clear that the true explanation might be rather 
more simple: All carcinoma of the cervix in any 
individual patient must start as Stage 1 disease and then 
progress through time (which may be in years) to Stage 4, 
at which time the patient will be older. A population of 
such individuals will have Stage 1 disease at a younger 
mean age than Stage 4 disease (or Stage 2 disease). 
Thus, instead of a case of "young patients more often 
have early stage disease" it is rather a case of "early 
stage disease is found more often in younger patients" 
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Having considered most aspects of the study, it re-
mains to discuss the literature which gave rise to the 
motivation for the present study, i.e. the literature 
which claims that carcinoma of the cervix in younger 
women has a worse prognosis than in older women ( and 
therefore might be a different disease). Once again, it 
is salient to consider the study numbers 
terms of the number of younger patients: 
Total Number 
72 Yeoh & Spittle71 
254 Gynning et a176 
131 Dattoli et a174 (Stage lB) 
220 Adcock et al70 (Stage lB) 
55 Chapman et a170 (<35) 
264 Mendenhall et al72 (Early Stage) 
561 Prempree et a175 
246 Buckley et a124 
5258 Lindell 78 (210 under 31) 
1085 Stanhope et a177 (265 under 35) 













The study by Elliott et al, which is Australian and 
hospital ba~ed, contains a group of 418 younger women -
the largest in this listing73 . Multivariate analysis was 
performed and it was found that the younger group had 
significantly more early recurrence and more lymph node 
metastases; when node state was allowed for, age lost 
its significance for death. This suggests that there is 
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more occult advanced disease in the young group. Another 
large study by Lindell early in the century was the first 
serious work to raise the suspicion that young women have 
a worse prognosis. 78 The difference, however was small 
(10 to 12% reduction in 5-year survival). The most sig-
nificant current study prior to Elliott et al was the 
work in 1980 of Stanhope et al from the MD Anderson hos-
pital in Texas, who found survival in the young group to 
be significantly less ( p = O, 005) . 77 The article has 
several potential methodological problems including 
choice of controls and an absence of primary data. 
Another article with wide influence was that by Buckley 
et al in 1988 where evidence was presented that mucin 
secretion in tumours is more common in the younger 




This data is not accurately quantified 
Chapman et al 79 and Prempree et al 75 do 
actuarial survival curves; the latter 
article finds the decreased survival in the young group 
to have a p-value of 0,03. Gynning et a1 76 find a value 
of less than O, 05 and Adcock et al 70 find a value of 
0,025 based on 26 patients. Yeoh and Spittle have only 6 
young patients in Stage 1 and have a p-value of o, 01. 71 
The largest difference in survival between the two age 
groups is found by Dattoli et al (1989).74 There were 43 
young patients in the study and the p-value was 0,0001. 
The literature claiming a worse prognosis in the 
young patient can be seen to be open to doubt, especially 
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in the light of the work reviewed earlier showing an op-
posi te conclusion. The present study provides results 
very much in keeping with the world literature experience 
and contributes to the evidence that there is in fact no 
difference between carcinoma of the cervix in the young 
versus the older patient beyond a natural fact that early 
stage disease is seen more often in the young patient (p 
= 0,01) and that surgical treatment is used more often in 
the young patient (p = 0,027). 
FUTURE STUDIES 
A future direction of study to explain the clinical 
impression that at least some young women do badly after 
treatment might lie in the entity of occult advanced dis-
ease. Perhaps the young women who do badly have in fact 
late stage disease ( and are surrounded by women who do 
very well). Seeing that young women conceivably have a ., 
different cervical stromal response to a cervical 
neoplasm than older women, it is possible that what 
appears to be disease confined to the cervix in some 
young women may in fact be advanced disease. This sort 
of occult advanced disease in the young could explain the 
"so called" Stage lB case with a poor prognosis. As 
hypothesized earlier, this situation might be more common 
in the young patient. Research efforts should be 
directed at identifying those patients with occult 
advanced disease. A related aspect which has been poorly 
explored in this regard is the role of the immune state. 
With the advent of the AIDS era, the technology for 
assessing cellular immune status is well developed and 
could be employed to answer this question. It is also 
conceivable that the hormones play a role in cervical 
stromal irnrnunoregulation at a local level. 
for example, only occurs in the younger 






Age, immune state and steroid hormone state may all 
relate to occult advanced disease, a concept which 
deserves further study. 
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5. CONCLUSIONS 
As a result of the present study the following general 
conclusions can be drawn about invasive carcinoma of the 
cervix in local young women: 
1. General Patient Characteristics 
The general characteristics of local young women 
with the disease are compatible with findings in the 
literature. This applies to age distribution within 
the young group, mean parity and rate of disease 




The disease is fairly common in women between the 
ages of 20 and 35 years. There has been no recent 
local increase in the proportion of young women with 
the disease. 
Disease Stage 
Early stage disease is seen significantly more often · 
than in older patients. 
Pathology 
There are no major differences in the pathological 
features of the disease compared to older women, ex-
cluding those which might have been detected by a 
routine mucin stain. 
5. Cytology 
There are no major differences in cytology results 
compared to the older group, within the context of a 
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generally very poorly utilized modality in patients 




Radical surgery is used significantly more often 
than in older patients, even if corrected for stage. 
The young do not receive better treatment than the 
older group, neither do they experience less 
treatment complications. Vaginal morbidity 
following radiotherapy is common and death may also 
be a complication of radiotherapy; surgery should 
be offered to the young patient if possible. 
Evidence of Human Papillomavirus 
HPV was not significantly more prevalent than in 
older women during the years 1974 to 1983. This 
suggests that it is not a new factor in cervical 
carcinoma. There is a lack of positive correlation 
between histology and cytology diagnosis of HPV. 
Survival 
There is no overall statistically significant dif-
ference in survival compared to older patients. The 
young patients do not have a worse prognosis even if 
the survival data is corrected for confounding 
factors by multivariate analysis. 
10. Policy Recommendations 
Young women should be recognized to be at risk of 
having invasive cervical carcinoma. The treatment 
should be the same as in older women except that 
surgery should be specifically favoured. Occult ad-
vanced disease should be looked for in patients of 
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